var title_f12_12_12480="Acute interstitial pneum CT";
var content_f12_12_12480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of acute interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 287px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEfAV4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5g0rTrvVdQgstOgkuLqZgkcaDJJNfWvwp+E9r4b06KbUFSXU3AaVgcqp9Afao/gJ8Mh4S0saxqwP9s3sf+qZcG3T+7zzuPf8AKvXXYYCKAB7UAV4IFhAxzjpU+5uvc0qAY56+hqRflXc3PtQAkZKYJP4UtxM0owMAelMYFiMc0+G3kkOEGSe1AEKJtBB5z2qeK3lc/IpIrVtdMC4abn2FaSqF+6APoKAMWHSpX/1hxVyLS4k+8zE1fpaAKgsIumW/OpI7WKP7q/jU9GKADJx1oyfU0jEKDlgB3z2oVgRkMNvrnigB2T6mgscdTSDkcH8aORQAu4+tG4+ppBSd6AHZPqaMnB5NIaKAI5YFkUgiqclgR9wg+xrQqIw5fd5jAelAGa1hJkkEinrZy7Ac85rTUY75ooAzvsb9Wxke9DWkhBJAwK0qKAMZ4GXAKdaZ5DmTpk1udRSAD2zQBiLazbyCvSpVspSfQVr0UAZH9ny/3qY2nSAHHNbVFAGAbCfHyrimCwmXJKtXRCg0Ac2bOYKSwOBzVV0Yeua64gH6VDJbQyAh0GT3HFAHP2d49qrbTliOc9qW8vROwxH5Z7nPWrF3pTIS0WGX9azzG8T7Xzn3oAesq4ww3H+VZ+qaPp2qQlLiIMG4watFSTk8Gm5ZDxmgDyjxX8DrDUg82m5ikPIA6V4j4x+F+u6HvElu0sQ6Mor7Nt7qRGyD0qa4ltryMxX0CSAj0oA/OG5t5beQpMjI44INRYr7G+K/wb07xBps93o22K/jUuoA+/7V8hahZzWN5LbXKNHLExVlYYIIoA/Q+Zy7tuOe2eoNIingU3GHJwOvWpkXAz2NAARnGeKGJZgD0FIMk4q5ZWxnYL/D3NADbO1e4c7RhehNb1vAkCgIOfWnxRrGoVQAOlONABnrmjijvR6UAFA/Kq9/e2unWzXF9MkMK8lmOK8b8ZfG+3srh7bQIllK5HnMM80Aev6nq2n6Um7UbyG34yFduT+FeXeLPi3HEWi0IBlBw0nU189eI/E+p61qsl/qF08su7ON3yj2rVt2juLNL1VAZxgqOx9aAPTv+E6vpNPaBpD5spDsxPIpNM8aXPkzW0l08cZOJDnNcbpMUV1HsN0I5AwBDckikvlJ14pFjyOAWB7DvQB6vaeKNRkt4LO1m821Zx8/RgPSumtvF72OrNY6oQ4A3Ap156CvBb7WZNOuY309vMQMBXZ3XxCtIUsZo7OA3u0BmZc0Ae8Wlwt1brMgYK3Zhgipa868GfEm21abyL90UscJIOPwr0RHWRFeNg6noQetADqKKKAA/Wij8aKAEpaKKACgUUUAHaiiigAooNNXOcE5oAdRR3o70AFFISqrucgKO54rIHiCxE0iSTooU4zmgDYoqCG9tZtvlXELlhkAOMmp8YoAKimginH7xAT61LRQBiX2muuWjJZP1rPyy5GPrkV1faqt3ZxzqTgBvWgDmdgJ6nNP74NT3VtJA2HH0IqvkhuRwaABJTGw7mvF/jN8IX8V6tHqugIiXUvFwhIUHjqK9rVFZfeo9rA4oAkWM7vm7c8UjMo+UDgelSs6qrHOG7GoUGFLt+FADo0bgdSegrpLSAQQKvfHNZOkR+bc7mGQozmt2gAoooHagA6e1c/4v8U6f4Y017i8lQyY+WPcMk1hfE/xxY+H9NaJLgfaycbVPNfK/i7xHeazdmW5md1PIBPAoA6D4g/EDUPEtxI0szpbZ+RAcDFefyzl2IXOP1ps0gMasWJ559qlitJbpk+zrl26g8Ae9AF2GDZHGh+Yv8xrpNJglg0zgb43k4P92sLUJRZ3KW5w5QDLLXQ6VOttpPlyPtEj7kHvQBLbMtncNIFxI3C5qDUpZQWZCRJ3wabtlmC3CI0nOBgZqe7gKWwmdNsjn7pPNAFrwXqEdvdXEWoW63ME6FAH6oexFUtd0qWy82ZC0qEHZii1iEcPmgEyA9q1VlXU3j03zjHIBnJ6ZPagDD0Zbu2e3aJmEmQcelfQ3w88SlI7e2uXIDnDlzwprxcaNc2lz5dwrCWMjaF53V6R4d8N6lq+mySpmIW43AnueuKAPWtS17TNPgEtxdxBScKFOSTXL6v4/SGUxadamYgcsexNeUaotyL0veuBHCpCRn+JvWsmPVrm2nMUr7ZSCRg9+1AHceK/ivqWlSRxQtChx8wZMnP1q/ofxeR7CG4vgkjNwyKuDXzhq11fajfyNcl3lDc5qxo7ztP5agkA44oA+u9I8e6TqABy0YK5+Y10VjqdnfRiS1nVx3r5N0my1e+u1gs1kdl4wPSve/BuhXGi6XEtzIfOYbmXPSgD0ESoc4YfnSeYmfvCsFPMJ4bjvTg7kkA85oA3d6+opDIo6kVj/vMDcTSSMyn72QO1AGysqE4B5FK5VBubj3rNtLoAqpAz39qoeINX2y/ZLKZEuyM4fv8ASgDowQVyKgvbqCyhMtzIEjHc1BpYmi01ftDbpQCa4PxzNeRWqiUGaGb7vPAoAo+MPFVzeCWGykZBg7dhyDXj11qF9dNiCR1fcQ3zfzrsJdOup7Tz7FkEiNtKk4Yg+1Yd2Le3lntxCRgDe+ec+1AFLTNTv4ZmSa4YonAZW7+1ek+DfH0mnExarevcoB/qz1HvmvP9IsZQ88/lKYivBJ7VnwvnU0UHG84KgZJBoA+ptB1yw162afTpg6r1U9RWma+a7TUJPD126WLPHHEd+3JyWr174f8AjqDxFD5F6Bb344GeBJ9PQ0AdqxPBHNKKDxgY/OigBk0SyoVcZFYt1YvEM/eT1Fbg/WggEEEZBoA5SVdhyvSpIpAfvYz71o39gRl4uR3FZToQeBz6UAPkHzY6gdxUZIJwB1OKM49eat6daGeXcfug5oA0NGiMaSFscmtKmogRcKKd25oAK4H4reOF8KaWyWzf6Y68eo+ldrqV9Bpmnz3124SCFS7En9K+O/iT4ol8T6zd3W7CqxCLngCgDnte1671m/e5vXaSU5OPSs632eUzS5YnoKpsSg9S3U1o6ZAhT966hfQ0ASwwxyWnlLCu8ksSOtVZ5mtIGt4W+dj85z0qfVL5bZfJtchv71ZEfztmQHdnlqANCwEl1cxxAFh3z2r0aHR0vdJV4JFCRHBJ7Dua5jRbYPaS+Ui7kTcz+or2fwx4FRfhZPql1cH7VOvmxLnCoucY/GgDz/Ur9Uhht9OjWKKP5V7Z9Sax5nkScvP8yD7xJzWvaW0kRmiuCjAnK8c1T1uNvsxRFAyQGPtQBSi1CURn7LDk5wvc10vhHw615PG9xNHBPL8w3tzWLpsSIUaNclevOc1oWE7Q63EG+fLAYB4FAHpOv6bcaRpiynZPKg5lznj2rltO8YanDHMv2iRLXONq9z611Mkz30clu6Ys7cEtnq3HauFi1ewhuZFmtyYiSFiUcA9qANW5t73Win2JTKw5MjD7tVrVtL8OXDy62P7Q1NwREmfkT61h6t4jvo42gtJzZg8FF4JFcjbyTzXmHkZ5M8MeTmgD0CDStP1rU45oyyibO+NV4B9K6Wx+FCQ3cEjSNCrHcynritr4V6HLY2DXN5FtnYjYGHb1r063gkmQDGSerN2+lAGPpGiW+nMfsUCLhcFj1Na6oQu5/wAKvwWSxgbmJNWGhQ9qAMMkgE4xUYcKOODWzNZK64U4NZdxYSIxPVfagByzR+WSxO7tTIV81sBsZ5yarzKy444qMSMG4Gc9aAH3Ti0EkytuCAk8+lfOuseMb688TXNzE2SknyAHOAK901/eNGvmjcBhC2AT7V8nKz217Jvb95vOSDweaAPpbwj44GqweTe3AWQrxjuPSrfiDXdM1TwldpYkJfWTeWsbNnPPWvFvBoljm+1khEIKhSazWv7ltVlMTMgLHcp6Ee9AHcS3LWFktzNeR/bdvzRA8jPQ1z3hXWjaeI0vLxFurZWJmik6MKLWO21O4ULIY5gMFH5DfQ1WvbZbe/2QoHA68cMaANvVPI1K+uLnTn2Wu4kx7sbR6Ad6x5meFWdX/fxrlTjkVkajPPYWjyFSjyNhRjGR61c8NXU18pWZBh1Krxkk0AbOgj7ddwm8uWcty4A+Zj6U/U76a21N41SS3ghb5QOHJrKtrj96sIJSVG6gdwa6XV7+DX2hXYEnhTaWUZMmO596APQPBXxJi8u00i8WW7vMBfNLYOPevVYnEsYcDAIzjrivjuz3WuvNdwySQiNuZDzj2r13wH8SrWz1JdN1KVzHOwCyH+FqAPaqKRSCoIwVIyCOmKXtQAhAIxWTfWZEu6LIDdQK16VfpmgDk40Ms2AK6OxtxBAAOp61jacVS4DPxW4s6MwVTkmgCUdKTJpawfGuuR6B4eubsuEmKmOHPdz3/CgDyT9o7xbJGkegWTgIPnuCDyT6V88F/NtpcAhwQMeorqdfN1f3E9xO/myyElmZuaqaLphaTZJGGDjrQBzYhBULzvOMA1fghK3BhlUow4waLvTbi3vW804KyAL+dd7e6bHqMts5QPN5Y+ZRgk4oA811S1laYsFJUcVVAfATke1eh6lZeTciCJRt2gnPY1Qtra2t7hzcRBpu3HFAFfwus0SBnysLkAg87q9Fn8STNZQ6RbyPFaR/MV3cDiuUkj8uGB402kdyeMUkki3EpKk5AyxHegCK+vvkEqs27dgt7VGb6C7ibDtuAwAx70Q28N9ObeWQxAKSpHeszT9LuLrVY7CzjeWeVwiYHWgDqfDMSyWE/wBomjgVRxIep9q2/D1vp9jcC71D97I5zCM8fjVzxZ8M7rw54etrm6laRQN0xQ8K3oa8+uNZUtFGhyOERR6etAHWahr1xfXd39lJR8nCZwMCuRjuZ769wzqDuwfalS1eczywykyYwoB6is82l4k6eTDLI7HGxATzQBLcaVqF1qxjy00rn5cc5r1vwH8OP7NEd9rqAuCGWM9j711Hwm8ByQWltqeqxmKYgnYw5xXpes6X9thVI2CbegoAo6FbfaXMxGI14HHWuhCgDAGKgsLcWlrHEOdo5qx3oAKSlooAKQgEYNKaBQBnXcB5O0EDpWTPEVAPY9q6YjI/Ss2+tXX5oxu4xgCgDivFyFvDt9jg7COa+W5EWK/fzOdjZ46V9feINHu7vRLuONAu+L5QDyTXyn4k0280zVJFmiZWJxyODQBu2M4uF2InOA21R2p7oESVyBGT8vzcVF4H1iDRdbs7y+g82JHAkQ8jFbPj9rO51mS6sgy28p3xxdgKAKGn2uCxiX7q7t4NX7fVJraCRUhjZwf3bMMlDXPpcSWRDtIQjg4UdKmcrPaxtLIyqWLDHU0AO1Az600FvIBLcHjGMU+zsGsLuGITeW6HhgeB7VPpTWlm4lMsglRd+T39qiF3b38kgETMzNuBJxigBhsntNedJzlQS+c9Qa67wzd6dpTXGoarCrWcSErjjc3pWONHvNZ1C2likxGI8St/dArA8Y6gmrWy6fpGRFbsQzHgSH1oAq6n4og1XUJUWFLW1ZyURRgViX1xFHqSmKTLxnIINQw6aJTBFLkSlsDAqvrUMFtfOlu+7tmgD66+DXigeIfC6QyyBru1G1ueSvau+r5H+AniGbRvGFvbbsw3B2MD0INfXLDBPoKAEpV60lOXrQBztvCxxngnpWxbQBFVmHzY/Ki22uA+0AjirIoAQDJwa+a/jR4tbVNentreUtaWreUq9s9zXqfxS8W/2PZSWNpJtmZcSODyPavlnW2kmvpZYpdyseRnmgCvezsOrZz3q/otrcTwo8LOmD1Y4FT+GtI+3MzXW7YnTjr7V0MsUFu4hjQlAQQKAJILLTtwfUyZZVGfl6ZrpfB3inRNI1mC4u4g8Odu1hnb71yFyCqA7SCGx9BVKTTxJI8pY7G4yOxoA7r4m6ZZPqUmoeHZA9vON7gdq8zdZJWDK3BODnrVy2uLi3nkgeZ9vQgnginK+L0QNB8khABoAbf3jyi1i/5ZxDbgd6SMSwRSzQxs0Z4baM7RWxFpg+1GPyxvUZ2mksbjyZblYyoiZcFfWgDndKRpZpZVOCvcnmu8+D80en+Mo7u8cMkSMQWHSsm30Yyq08ETeUq7347VNp8sdnqt3cIrLbBVRAfU9aAPTPjf41SPwtFYWsZAvcMXJyNtfMyxN9oLxE8HjPQV7V4oto7nT4Uu/nwBJETyMeleN+ID5N60kQxCGwuO5FAHrHwh0KLVL6OKaCR5ZDuBxxGK9+8P+DtF0KWSa0thJcOcmWUA4+npWH8FNJOn+BLG4uI1F3dL5jNjnb2Fd9QAZOTmgdKKKADvQaBRQAUUlLQAUUfWigAFI27b8h5z3opaAILq4MAUlevU9hXzh8WY3/tea5Lp5W/AVe9fSxRXXDAMD68183/GXTpI7+4W3VnYOeO4H0oA4DT7OM3RE0oeHrkV00sC6jZLZq4juAP3Dk9f9msDwnpdxdPNaxq2Su9e5BqzLFdpIYwjbozknuCKAK9zpt6swgniJaMAAkd6k1QJb2iRujCaNfmHZc112keMIItOWyuoIpkVwGdl+dT9a2L34ZXWq6Y2q2FyLmK4+YRL1WgDx03DeWMMS3cmtjwo4a4aIxBi/Kk+tafiLwNe+H0inv4mRGP3O5Fa3gnSrLUngcGVJxMABjgUAdLetF4Y8Hx3SyhdUu2MZhPOEPfFeW74EuJCLRlfO4gHgmun+LMl1a6z9nCGW0hOFdeeaq+H9KOpXtjCYy8VyQoJ9c0ARaLZWd5DLfXDC1ijUqHYZAauQHhW+udSyhDxM2RMfukete0fGKzsdJisNI063iCQRgz443t71ymoiGTwenlTeUE5YJ1X2oAy5vDcPhq4s7yO6iY7gxcuOPwr6k8LatBrOhWl1bzLLlArkHuBXxTezfatkYeQqPU5r3H9mnXGWW80aUswYb0J7YoA96pU6800nDYwefTtT1znrQAxV2DaBxQzbEZ+ygmlNUNeuFtdJuXZgo2kUAfPfxEhudS1C4eVjlmJNea22gXl3OVijLc8D1rtNT1gTatcOXYKxIC5z0rN1u7uVigazfyVUfORQBLYW82k2vkBD5i8kZrdSOHUUiCxBLsKWOBXLadq/m3ATUCfKIPzDrmus0DVra0uFliVH8ojr/FQBBrejTaZaWhvl8pZwSpYc1hNC4iMceCjd89TXunxB0aDxl4Ss9UtZ0hkgj3Z7D1FeHwt5V0bWNVkK9ST3oAxZ0aGVjcL+8XoauXUcUGoWrWjtKXQOwb+E1Nq0B2qhAaTOWf0qtGRLdRoch1H36AOwTSZruSG5jIQsMu4PH0rAl0G7i1M26Ald3BI4Oa3PCmslb4WjnfGWGRivfdI0XTzbRyvbRSyfeDEZNAHm9vpv9g+E3SWMfaZELZP06V57ZaZJfWIhkbbOXZ2TuQfSvoHxT4YOrhWt5hE44w3TFcxYeFz/bq2rR7vJXLSBcEj2oA4S6kC+HEshBvliUoGb7wryXU9P87VLeNMsGlVCCPevpXxp4a+wiK5hcCFztYheR9a80j0gy+KYPIgDMkynp1Oe1AH0bpFstno9jbKu1YoEXH4VbpAfkUnrtGfypaADvRRRQAUUUUAFFHSigANJS0UAFFA6UUAFed/EzToDewXLq2ZVwdozyK9Erm/HiEaN56rl4m646UAeEXtnN4c1J7q7jYIw3KyHAwegNRQTW9yvm4w8hyAOaoeJfEV3LNcaewEkVw3KkZPtg1zcaXul3Qjky6AAgA/dHvQBo6nZPCZWVRhiWDZr3z4J69FeeDVhuZkjltHwd7Y+X1rwObUVvraNW4kbjPt71U+1TaZNJ5E7orIdw3UAemfFnxFDf8AiNUW43WvEaHqPrU/wy09bbULqV3IhRCwPY8cGvMvDOn3PinW7ayjJIkYD5ufxr6PuPCMekeFJbfT2eW5RMMf747/AJUAeJeIJWnvJycM0rHaW/iGa6nwDpeo6Vd6bv055InfzFf+7isrWdKuFS2MEatIg3F2Pv0rpk8dzWMFoSyq1ooQpjhz3oAqfEO8W41+Uajb+VJj7pGPzrkbeGOS2vLfChHHSqPjzX7vXtdmv7tdicbYwcDFZljrUsO87flIwMjNAGpDoccEJ3KrbhgYWuw+HlzpnhLXoJbmI75R5ZYfw571ieGbiXWZ4beMrC/0zzWhremRIUjkEm9HG524yfWgD6KidZI0eNgUYblPqKj850Y70O3tg81Q8KTC48OWDqcgR7fritGacRYyCQfagCQ8E1558ZNbOn6H9miB82QZ4GRXoh+968186/H3xFdr4mWwtZV2wgDbigDzG+ZpsuHKyD7w75q9oup2l3MLPUCy25Xa0g65rIF7yXuI2WRzk4HBqwtrZvMkyNIgbllI70AdVqPguEWqS6bqCXCscbc/MtMuNMuNHAhmC7wM8GqiGWO2M1ixDg9PpWst8+sWcFtex7LjGA54JoA6HwjrRaxnsbrd9kddpyeAa5mSC1stTuBAd6qCQzHqa6i98NvbaVavph85iuZVU8g+lJL4YbU9LiZYWjnHBUdTQBxHnm6Eisu1/WqlvbM91IhDB413EDuKszwXml6vHbyq21jyGHSugs7aKa7fzIz++Xy/MT+HNAGP4ZvorPxFbS3a/uC4VgB0Gete26l4g/sbxHBHpkgntJkVsE9favKo/C1/IVW1hE8ath3A5rotRaS2uraONT50AGcj0oA90s7gXNskoUoW6qexqbA64G7pnHP51x3gjW3vr2S3k+ZnjDkjsR2rsiMdRzQBBe2sd7bSQTAlG/SuWh8Itb+IYb2J4zAjBjnrXYUUABOSfeiiigAo7GiigA/pRxQaKACko7U0l9zALkAce9AD6KQdASME9qWgApO9LRQAlQX8AubOWEqH3LjB6VPSigD5m+Knh02OrLcQIINpwxB6GuS/tP8AswGC9SOaKYg+b1JH1r6W+I3hoa/pu1FHmDjgc14Y3h0WUklvqFk1xJG2Y93FAGLqejtZRMzqQjL5qnGBtPQZrjtTuJHjGScsf0r1rxbq9xqmjQ2WoaesUNqg2lON47DNebWptb3UUacRxRxtyucjA7UAdR4LtJ7Cwt9VtjJDNG/yuK9U0T4sXX2gQ6nbxyRAYMirye3NcE99cSWS29mqeWBuVAcc1Tv38jT/ADQSZJP7o4BHagDt7q5WfUrp1t41QguTnoK8+1q7kvtTghgjQQM+G2n9c103h6CW58J3TXUj/bJ1LI49PQ1jaXoJtoWml2kk/KobvQBS8ZoljZWoQxmUDgnnI+tU/DgtLm3aSaF3kx0/hrSvbb7ROILtCyBuB1q34unTw3oMGnadalLiYeY8zrzj0FAFn+0odItEeNI4pyQfk6rVXxZ40GoRRLsI8sfO2cbj6mvM55L2eXzCXbnJYdjU1xBeNCPNwFYZyT1oA+i/gT45TWbeXRpQBLDloznr7V7AoBPzAfiK+L/g9qj6N47svm4dwp96+0VwxByQCMigAGPM9ea+SPjElxL8RtQ/ds6rJgGvrcffHpmvlr4j6lu8c6ox4QTHDAZBoA5lLGRUDzhSvGFbrVvT4bG71YWk0RyR1DVUvbu4vJFbZmNV2gjiqtvY3z3iyIrKwPBFAHa3tpAvlRRxsgibgg4z/jWfPZ3DKjwo8jRv8pHWtv7X51vbQyqrmMDc/qa1rdLeOZjFJsDAHZ70AUtJ1q90yxuI5Y8XD8Anr9Khs/EFza3TNKxBIyoBqteXXm3Usc5yqNkZ6gVga3ctayO5CEHkewoA3dQ1E38LXjwEvHwzMOoqlpU91d30UllE8Sxn5yOn41kabrrykQMuUYfd65rsrbVxa6JLbQxCN+GeTHOPSgCU+KZdMnZbFt828Hcp6mtTxne/2vdw6pEgjMcYEsad2x6V5vbXjyavJ5YVN7ZUn1r13w94du9W0vfCI9xGWk9T6UAcf/wk2pWVoZtCgkSc/KWUZNdN4A+I+sALb+I7eRmJx+8XDLXdeFtHtdFhFlcQrLdSsWMpTp6AV0Uml2UoxPbRSPjBcoM0AWbaeO6t45YTlHGQTXJ6l4rWLxNHYQLvjQ7WI65rpNPtntC8SkfZ/wCAdwa53V/C8Z1a3vbQbZDJmQ0AdaOgOMZGaWj0HpRQAVw/xA+Jmh+CZEgv2ae8YZ8iM8ge9X/iT4rh8HeFrjUpMGX7sS+rV8L+I9cvte1i51C/mLyzMWJJz+FAH1Ponx/0W+1Rba7s5IIXOFkzyPrXpmqeKtM0/SV1AzrJAy7gQeor8/YpmDZB+YHgiuz1Xxjd3HhOCxMrHb8pGe1AHvUP7QWnvq7QPpzC1BwGDcn3r0vwh450PxW5i0q5JuVXc0TjDAe1fAnmyZBDEGu7+FPiWTR/EMcvmtHJ/Cw/lQB90UdqyvC2q/2zo0F2Vw7cNjv71q80AFJS0UAFGM0UfjQAjciub8ZafHPpdzKkEYnCcS/xGulrO1hkktJYlIklUFvLByaAPlvxJe3ruIbpyqqPKUVk2nhW9iJaSHd5g3qFGd1et23haz8SPerMJYr9shBjge9R+IPB/iLw/wCGjaaHI1zdQupku27J6DNAHk0V29nqcdtcBgd2CucEe1dA8j3MyQqrC3b7ox0pur2JudUjnlto1nIBL9Sx7kVuW5ukaCICPzFwfu8/SgDt9J0jTLPRxBeyyC5WLA2t8vPOKr+FfD0GpzTxvGBbR5kMm7IwKTxVcFdJt5YLdSznZMegLf41c8INc6favMsexMbXifuvfFAHO+I4rSxdriBsrCcxhu9Y3xl8SQ69p+izW8aq8UeH4xz/AIVf17XbDWtQZIVEcKOQoxwa5Xx34bnjsEmTzHcjcdo+VR2oAyPCsNhf3vlXtw1tHjcxOMMfaruuwpNIy20ISFDtXPcVxkUcdsI5rmXzCG4jU84rtri60e706O506S4aQriSJ+x9qAOXsNPl03xRYTJgr5oYZOe9fbdm2+1t3GctEp4+gr40srO51fUbJLJCZklHy57Zr7LsEKWlsjD5khRWHoQBQAzUbpbOxurmRtqwxs5P4V8iazr9vcahK8qCTdIxLdD1r6V+K109t4NvvLBPmZQ49K+NWjklkchSVDHpQB6NoclqziSZSbZj93HOK6LUNEhitvtelzN5DdVfqtcL4eu7ZwtrM5BGMHNdJYSz3Estk4cx84bpQAIcKf3gG39ajOuQrPG5YNtPNQyaXeJMsW1gvQMayf7Mnt72W2vwAQCUx3oAvapqCRp5sEu+WU5KMOlVLHQtU8RzeYE2xLwzE/L+FQ3duYbRZGXcMEDNTeFNW1GytJbWLd5O7cQe+fSgD17wr8JrD+zY7uK9Es5HAK5Cn0rL1/wNqVhFcbWEhcHav96l8MeJ78xPFY+fCqj95xxmug/te6txDfS+ZI0nQSDr9KAPL9G8I6hLdxyzQsXDcYHAr6B8AaXPpOiGG64d28zHpXJ3vi37RPC1pZ7FONygY5HU/SvQPD99JqWmrcyoFJYrx6UAaDKHZWKgsvQ96UAnoOabK4ihklbO1FJNfPuvfFjU9S8SvpmlbkjjkwBH3oA98nu4YLhIpXAcjIXvXzLq/wAZdYi8fXVmm+OKOYxrHjgjNelxau6PG+oPI12se7Pp7Vn6bY+ENS1I6pfWKm6DZc98+tAHpfhXXP7Z0yKaRPLnI+Za3O/WudttW0CygiaCeJA5CqueRWxb6jZXGPJu4WJ6DcM0AfM/7TuvS31zFYqWW3gbG3sTXz6cd6+0/if8NIvFQknhwsp6/WvCLn4Fa/5zCKWEIDj5qAPIioxkHBrWOi3j+HP7V8t/IWTZnHBr2Dw5+z5d3UgbUL0OqnmOIcfnXst9a+CfCXhi08N63LbW8RHyrIM7ie+aAPiNXBGK2PC1pLf65awW6sWdwOK+j7j4M+DdYVrrSLhJEY5xby5H5V0nw0+F2i+HNVNxHBJLIgyrS84NAHoPgvT30vwxY2sgwyrkj0raoooAKKKKADtQPSjHFFADZHWOJpJDhFBYn0Fc54UxeXV7qG5XLuVV88gVY8aQXl1oUsOnczOQCB1I9KzvBOlXfh/S5W1Er5krAiNTnaKAOohtoIXeSKJEd/vMo5NR6ssTaZdC4BMJjO8A44otLsTrIzARopwCe9Z+r6xpyo9rcyK0UqEMQeKAPAvH+ppFfQzaZiNV6pt4A6AVqaXK9/b2k+FMpxuYHoB7etP8Y+F2WKW8giee0zksnIT0rL8Dx3SGWO0gLSMCYiT8qmgD1rwRbW2oib7TD5iQncok5BPrium12OKPS7gokSPIDGCQAK87+Fs3iqCx1mfxKsKkOBblQBjnqcdq1db1i7n2wTJE6gZbn73pQBwUvhjTYpZrvDoI8uyk8E+1eZeKfHV/fXhtoZStrHlPLHQj3r0P4j6wdO8MTLHL+/mO0nHb0rwmKDCfaJdxYndjHBoAvmMan8scPlSnsh4NattCbECMuAAOo9aXSZFmVGtCrOOoUYIqhqIe4uwqxujg4IYYJoA7TwXqSaZq1tdTyIVDghfXn0r6zs51u7eG4jzslQOPxr4wt41thGZIyHUg+4r688Gzpc+FtLlBODAB+NAGT8VLVrvwbeIkmwgg59q+VLrR/ssTgTZk6nBr7N1eBLrTruKVBIrRn5T0PHFfKWrtLb+IZrZ408sscYFAHFaPcG31MCNA/ODursYNUmt70EyNyAQpHH0FS3+iR2mnzX9uiiVVyRjiuCuLu8mYMGcFemeKAPfkure88PoxiIuIvmLZ7VwGrBrnV0lUksRyc9BVaXWbuDwzZW9u+68diZlPp2q1okE80ZlnYg+h7UASgW17EttKfmzt64NeieAvBy6rCVuYvIgjXAkx83sK89TSwmsR3BOF9B/ervIvF+oaZbNbxTiN2jJBHXNAHU+INO0Hw/ZpZwTsdQIwFDDLexrB1/xPu8CpDcadtvoZdgbPCrnrXj9tqt5qHiFr+9kkJL7iWJyTXUeJLo3ej5t5Mg/NjOT+NAHU+Fp0mY3N5JshHCY5Oe4rZXxBfaJczLHuEBG6MEcEVyngS0mvoopbmKRE2nadvy1u6/dobSGJLiIvGfLw/BAoAl0PxDrfivUL2C3mnEYgYEduas+AvA+n+FLO61q/j+1ag8m0KwzsJ9a2fg7ZSWunag0yrzIArjuOtdhr8SyaXOmwYk4YjjHvQB4v4kuIoTd3yiaeYyZ8uLoF71zVzrmm2tuzRbkkm5CDt9a2LHWYPC/iny9RVZ4Wch0PIIrO8RSeHLnxHfSrAFt5lLhV/h+lAHK3eo3N62YhKyR9wcfjUllrGoLqFvJHI6rGQRknmm3d5FFBFCsZgtScZX7xFM062Q3DCCV2yeGYdBQB9GweOdPso7CPUp9rTRryRjBrsUEE6JKnlyqwyrDnIr428f6pL9ptYmmMjQoBwele8/ADxFJrXhf7O8gd7Y4IJ5AoA9UVQowoCj0AxXx7+0kviWbxe91qVjt0uP5IJEGVx619h1m+ItGs9d0e50/UIVkgmQqcjke4oA+KfhTr+pQeJ7OzsppVWZwCqtxX3HbqY7aJWJLBBk+pxXzl8Mvhgvh/4nlpiZoYWLxHHQV9JtnJoASiiigAo9KKKACkJAHNLXK+JtfS3Y2/kPIA4AKH7x/wFAHVA8U2RFddrDI61S0m7e7tg0kYjIAxz1rQHBHegDF8QXcdpot8bYx3E0aZ8lSCR+A5r548TeIbmea3j3lZWYKVwQFrs49Ns9K+Mtx9k1G6mmm/1tvklQG6g127/DPQZbrzrsSzMH3AZwBQBx+kand6dYtkGeOdPJKuMrg1Q0G7tdE1CZFQNJIfmjDZKZ9q9K1DSLbSoZbpsNYQpvCNyQRXzjrerrc+M3uLRmVZG+8OwoA9f1PWbmPTW3lkt0BbavzBj71maXc3c+im7u7P7TaSg7PLG0g1my67Zw2MFp95lGZFJ4rq/D2rW62kNrHGSrKQEXkNn0oA8P8AFt4NT+WQMnlMVMZ5zWPcNbRWQUjd3+ldj8WAttqxhsII40fl8Lkg+5rg0D3CSxSFWbBwaAMu5mw5+zAxEngKcGuh8M217rF0shl3GEfMW6iuTVWYvvYJtPHqT6VtaTrV1bW0yxuihxyFGDQB0OsNaw3ODKGcDkepr6e+Et4l94D014sgIChH418TzyyzPJJljk19e/s95/4V9ApJ4ckZoA9IlQPvRvusCprwDxv4fi03xDJLI4VSTt9xX0AfvH615J8fbfZpdtdRxjKHBNAHDm7sUsZoJlEqOOhPIrAtNP0vUHctiJV75rhb3UZnn+WQrg8AHrVaLUriMnaTtY8igDsNXms9EuYUhImkY5znoK3tM1GK+0+chfujPvXmuPt0zPJIFbouTXYeFrC6UCMPGVcE8HrQBlt4jvJL8JbHdCj4wR0Ndvo08OtyxC9AimTv2asCPw3HbyTDo8j5A969h+GfgaKHT2v9bjWOA/Mqs2OPUmgDzG/8N32oai8Glx8LJ1A7V65oPgTRNM02KTxBOI7raN6u4UCmeIPF+hWE76doUcP28jIk7fQV474nh8S+IdRWXUZnWNmAHzcUAfS+ozabofhK5u0SMWVtbl0Kjrxxz9a+UJ/Ecmr35nbO92Jwvp2r3rWnt9S+ENxo8FyGuo4FQjPJxXhXhnwbqlneQ3UsB8iM/MT3FAHrHwL1y4k1W6s7gOIXjLDJ4GO9evR3lpq1rPFBLuUgo2OCK8J8ORLpf2l7OUNPICN2cYB7Ve0TU7jTxJI8si+c2wYPBNAHAfGaybT/ABK6xT70IDKfWuMXU/LEX7ws5G1t3Ndd4y1EX+o/YtTjcsjERyr94D0Nc2dDsZ2je3vOVbDKeCfpQBYhuWuryL7QFaHbsx/WtbSdVs0FzBvCqucFutYd9JEjeTDkCMYDe9YLFlDMxJY5/GgA1WcXWpMyvkcjmvTf2ZNZGm+Np9PlYrFeREDJ43CvMtLtg85kL84JIPpXoHwH0WbV/iBHcW6SGCzBZ36AD3oA+u/5UHpSBQoC5yB0pRQBVgsYIbuW6RAJpBgn2q1QKDQAUUd6DQAlLSUoBJ460AZ+uarb6Jpz3l2TsUgADqSa80u7fVNa1VX0qWNVnbexY42DvVn4rXkOoxxxw3irHbnZgHq/r9K5LRZFsI5YmvzI0hBwj8qKAPV9K08Q6pF5V88rRKFdTyG9ea6dmVVZnYKi8knsK8km12+0y0S80+CZohwo25OfeqjeKvEOv5tniaDtIiqQCKAHXOt2L/EV7ixiRJd43TgfeA7V7FHMk8KzIfkcZGT+lfOmvWmpWVubqxhAkiOHjxk49a3vgtfazrOpTR6q8/2OPmNZMquaAPW9fMEtt9nllRC/ZvSvEk8M2o1+eMeWS7EqoXJFek+Nrm3u5lt7OV4tWhdflZeGX29apauqaJbPcx2qx3sgDFnGWx3xQB5jq3hfe0qzAC4jJ2Kp4etTQ/N022toVtybjoJmfgGtnTlk1iWe5iOI0XzCCuX98ViN4nsWuHtmjWC3c7Flblg3r7UAS+KtCj1OaKVpUE2Nz4OQR3rg/FmlQW8LG0ZFZf4V9K6VDdm5VI3aWNGIDL0IrnriyW01Ca61F9turf6rPLe1AHmlvaz3Nz5EcbmRmwOK2m0Oa1uI4R/rgOcDpV6fxGkGpOthFFbRZyuBlvzq/pF9NqmpAt8wY8Af40AYOpaFdecGijLB8ZA7GvrT4N2Emm+B7SGUFXPODxXmnh6xtrrW7WBokySPwr3uzgW0hjhjAVUXHHegCRvvGuM+LmjNrPgm8WIZkgBlA9R3rsuhNBVZAUkUMjAqQe4NAH583GYrl0kzlDingqVVkDbz1z0rsPir4f8A7D8Z38EafullJHHY8iuQd90qKPlHQ0ANRyh24PJ7muv8Ja9HZxPBOoQHgEVz955JKoF+dF5HrVATKp+6RzQB9S/C/R7PxAjXkjiWCAgHI5Jqn8ZPFMhZNH07elmBtfyxjJpvwa1i20v4Y3bSzCO9llO0HgnjisjWLa41HT5Z4pF84Zzx1PtQB5YNLvWui8chk2cht3zLXWeEL03cdxbXF2DcIcojHvXEy/2haXMjSwTJI2QT61P4ctbmTXrUpIiTZyMt19qAO21691FriFtLlA2cSIp5z610/h29+0WG+5B2/ck3HjPrWJB5VpDPLcRMkhzk45B9qjk1y1W0kgtjtXALFuCcUAbjaYIYm8ht8BbAYdKrfEUtpi6YmnMHGxWK9SGNavgjXrO50250qN4pXuBlfM/hI9K84uvENzD4neHUU3GJ/L25zx7UATeMLW4S2/tC8heKfAwSOo9a4K3lMV2ZEYkMa9s1rWLWfQPsl1AblgARk9FPavM7fTbWTWFtIQYg57jPWgDKvI288ygHysc81kTyEOSBuRea6PxdDDpkv2VJfMfHPNc5ZxmZiUlRHTn5ujCgCxG8P2eOaOORbmQlGGfl219U/s/+Gn0DwYbi5i8u5v283BHO3tXhnwc8N/8ACUeNYIZ8fZ4f30ox8pUdq+v1CoipGoVFGFUDoB0FAC0UUGgAo74pO1BVWIJGSOlAC9+KKo6vqMemWpnmX90oLOxPSvL7341WQnaOztAfmxukOc0AevA/489q86+IvjqKwt3sdJbzrhgRLMvRB3ANcDr/AMYNYfeto1vbQjIIKglhXnl547ldWi+zIwkJyR1NAGH4h1y8udQlfznWAcAA9/Wuo+GdxHJLcSXCNc8ALnqPesJ44NVUiFFz6L1zXo3hfw0NP8A3N1Mj27yPjJ4JHtQB6mninwvZwx25lZ7wwjMAGQDjvWZb6tDqMMy6ZeWMEa/M6lwCT3Ge9eEPrx01p4Yts8bqU81xyD7GuZ0+7d7plQu7yN68D3oA+mvGWradplvYX8LRhHXZMg+bcfUU/SvGek3NvDJpkctvcBSjKwwD715jpmnXWt6XHp8HmsIju3sPu+tdZ4W8FRR6hZtc37fe2tEEOVPuelAHL6z401iDxVa6hGC0cMgJBGQFB6CvT/iL4lsdQ8HW9zZTMJJGDlduWC45H51nS+BLi2ur23hsTNbpKZI3ZuoNVPEfhXVJtKV7JY0iHyOpHT6UAcRpPjF/sU9lah7WQdJFPLe1ZMWjtcXBu2uNxd9xjPU1tW3hO505m8yS3lnPAQEZUetO1C0l061NxsDPgqGznFAHQCa6s7KSS3tYyhXAI5C15X4zubm+Z5EBUrxIq9vevRvAl5czRSQXuGQ8ozDj8RVxNLtRrE1w9rHskQrMu3INAHzo0W1gDyc9M1taFdfYbrd5gMbc4Bwc+lavjnTrTStRU26YjlzhSOVrllzExPBDenagD3H4Ua6up+KYLZmAwRjA5H1r6RUjcRgV80/sy+H5brWLrWJAfKgGAx7+gr6WjPJzQAhHzGkpT1NJ3oA8N/aC0EyXQ1GMD9/GFPHIYV86vbmFlaX+Fua+3PHGhHXtDkgT/XoCyD19q+OvGFvJZarJE6bGzjkdDQBjMTLOXUjmrGn2YlvYhINyhh9KrQoHlKgkPXf+HvD7rZxTSFN7HOCaAN+wvYYoBaMMQkZUDqDXYeDoElRIZZSPOYqgcda5nTfDN3eThskIvfsBXpfgWDSodVjs5rtZbmFTIoPTigCt4y0rRdA8OyPrKKbnaQi968F8JQS614uitrGItK0m6PaOgrT+NHi+fXvE1zAs7PbW7lFHYVd+C19aaA95rt8wLxIY4lHXJHWgDqfFV3DpMgj1KBSsfB+blvWvPNVMAtrm7gYtE4/dg/yqbxFcNr8he4PDOzKxPQH1qK10C7GjhQybckDLdRQBzukarNp16k0LHeORj1rb8WtHdx2upkmG6kOZAo4z61gvYSWV4rSlQUfJUHOa9W8S6DBqngq2v9J8ttwG9MjI9aAOPa4uruSzmszuk2BX9GroL+3i0bThqN6oW8I+Xt+lcRostxpmpr+8MYjbJRuaTxl4gk168Yh28tOAooAwdTuZLu7kuJecnOKSVYkggeNW+cfOp7Vf0KC2mnuodRVgiQmRTnGCKi0SybWNWtrKBTmaQKBQB9Ffsy6D9k0K91iVMPdN5cZI52jrXtVZHhLSl0Xw/Z6ei7VhUDHv61r4oATtRS0lAC0d6O9FAHlX7RGpHTvCVuqs6ieXDbT1x2r5dTUbhblXjQOWOAhHFfUn7QmlS6p4c08RruSOclvavnDXLKSyijFucyDksBwtAGdqzytdjzkCOQP3a9jVG5+VgGYhj0A7VsWF3ZS+f9rt5JdQZcpLuwq1lu0Uhy0exQ3LZ60AW/DF29jrUUhOeeV65r2X4ha/LD4J00yP8smfkPpXi0CRxzI5bCqeCp5NdX4q8SQap4ds9Oe2MTQHKyk5JoA5ae6a8jXzSioD/COcV6H4HufDdtcWDiH53Pzbxkkj19K8uhgm3hYk3knjHOa6rStNkWFnlRldVLFjwAfQUAd9N8X7zSNXmSws7SCxEmxoVQZYZ6k16PeeP7eS7soLa3jVZollV0wVJNfKV4ssyO5boec9a19M1y8geziBLCHhSvUCgD7c0e/j1KwSZDzjDr/dNYHjDxA2gwSxwwi5ldfkQcBM+teQaH8TJ9MXy1CgkdfWtdPFra+8ZvUVC4IyvUUAcnbeKI21e4bWLUKiNuQFsE1Lp/i6wv8AXbm1MJ8qZCqjtXB+JtVs7jVJovLdJUcrv9an8FWMF1rVvItyfN3/AHAOcUAetaXJaaZpxF1Yy7g3yyK3Qe9R33iKxFlOqqGcDcpBwc10Os6fBFobBd/mqBlzyG/wryXW7ZrGG4uH+ePGCAcGgDjvFeoy6lcFpFCqDwetYMETzzxQICzysFCr3zV3Ub9LkFAqoo6V3PwG8KP4i8XxXksZNnaHcc9MigD6T+GfhyPwv4OsbJVCzOolmP8AtGurQ89+lISCf0HsKVOvOPxoAQ9TTeQcYpx6mmsMqcEg+1AC5wc/jXiHxu+H0N60mqafE29+XVRxu9a9v6gZqG7t47u2eGYZRhj6UAfFtp4ZvUYtJDj/AGvaur051stPna5lXagAVveu/wDHvhifTLiPYcWbnl19K8e8a3UcWLSzkxGPUdKAPaPBF5BqnhO9ntLjzrq3Xedo7eleRHxLdWHiI3qEgqzD8K6r4PeILfRtMnRyoW5+Q8dfWq3xG8J2pnuLzSZt0e0SY+vWgDzHXPKlvpbpMlbhi4Oe/eoopZLewkVZtiOfmWlfTroQtKqO0KnGQOhqWLSb64sJrhIJHiiGWbHQUAO0/W5rd1DlXUDHI4NaNpqVy8BadXltQ/RT90e1Zenacl3E7BiHAxzXcfD4WNrpuo2GtxocjfC2e/pQByV/ZSbpJLdGlt2+YHqRWp4c1F7bTbm2nuJI4h8yqDxmrGq+Irazge1soxt6ZI61xpnaR2Lng84oA0LydtQvPLgwGbhSetUZbeXTLyMtInmIfnA5q3ol6LC/W6ZVcKCoX8Krqn21p9zKk+4vhu4oAj+2kyyEgF5Bgk16f+zhoTal42OoPGTbWKlskcbj0Fecafp6ahPHaxK3nSNtUrzzX2B8KPCMPhHwpBbKP9Km/eTPjknsKAO0ApD+lA60ZoAKKKKACiige9AHM/Eq1W78GX+c5iAkH1rwK48rWNGkj228TwrnJOC1fTGsWa6jpF7Zt/y2iZB9ccV8T6pIbO+uYJWkWWGRkIz6GgCxoPhx9au7yJ7qOwihjaQM4++R2FYsC2+ySKa2eVlbhlbGT716B8NdV0zyruS/tnlliXBDdDmqup2llDdSXNkyIjgsQQOKAONCIwAhj8uU9Cxz+FUZmdtyEFiO3Wus/wCEX1DUNIm1MywQ2kTfK5bk/QVy8Ur28rujkEcMwGcigCG0uJIZFaNijLziuobxAs2kNDcr+/AwrdBiuVRg0gZASc9+9FzIpZ1IIbvzQBYmiYW4kLD5jxtPanQTCK3dIyVRhgn+I/jVBJSigL93qQTWnpSQXspWQhHxxnoaAJ9OLT3MKSsI1XvntXqXg3VLeyvrdPs8c8cbcq3JNeVzPLbXDMduBxnHGK2PB2rR6fqjTStwFPB6mgDt/iV8PDqE/wDbGhKPLmOZEHRT6VL8KPBV4uorc3cJZo+RGvGRXP2fxOvNM1eVoBm0lG1425H1rsdB+IVkitL9pjTfzjoR7UAbPxRu5dJ02OSBH8iQ8nPQ+leF654gluh5QfG7rnmu08eePYdUt57WAq0J4KkZAPqK8tA3udg3E8AdaAJLKwm1HUbe0hUmSZgnA/pX2j8MfCcPhHw3DbombmRQ0jY5+leb/AP4avYgeINdhxKwBtoXHT3Ne7kknJNAAOlOQ4OKZ2p6dcmgBGHJpKVuppKADmkPFLSUAQX1nBfWzw3USyRsMYIzj6V8zfFb4d3ek3c1zCnn2znKvjjHpX1DUV3bw3ds9vcxLLBIMMjDg0AfDdtc3FqFhfMaJ2Wrs+vXht2j8+QgjAz1Ar3nx78JI7iJ7nQVDv1MLfex7eteC67p9xpdy8NxA0MifLhhjmgDrvAf2MeGbsajNgtJkA81csPF1nosF/ZxRRzW9xEYzuA4+leYm9nt7cwjIzzUcSrcpuUuZTwFx3oAsjUDDcSeRGEjLcYqG71Sa5lIYFVPAxVaYSQyrHOhUr1qW2hknctbgsQOg5oAdZ2kt3OFiRpF/ixzitTXPDx0NFkklV2lGQp7VW0RpdLuJZ3JWQjGCadr13PfustxIZBj16UAY5y7qNwUZ5rq/DtnFcSSRSRK7uMK2Oa5/TdOmvpfLt42fJ9K9m+GHgWW0l+2X5yf4UagDX+Dfw1i0/Wjqt9lljGYkYdDXu+efeuW03zEZVTPHZeldLEmVDOPnx1oAkooo70AFFFFABRRRQAAkHI618x/tCeDH0vXX1u0XFjfHLlR9x+4NfTg4NUdc0mz1zSrjTtRiEltMuGHcHsR70AfDNpcSWaeZAzgHg+9Purgzj53JQ8/NwBXX/EzwJfeDtRKPvm0+Q5hmA4PsfeuEnBePDcY7etAHQXUhs9Dtx50kkMoICbvlz9KytGvBYalDcSQR3MKtl4n6EVJeq8uj2bj5lQ8r6VWtZY0k+YYU+2aALGtOJtWdraBIIy25FHQA9qr6lHAboOrKwYDKr611OoW/h6exiktbi5W/Mfzqy8E+1Ydnor36mS3kUIPvBmGRQBkMmyTGxcH0ojVkfj5fpV6S3NpO0LsN3sM4HrVPY8pKruKr1YDigB8Ujox3fMvvzUskeULwZ981EsWBgFmOOTjpSANGwYHP1NAERwXBIBbOKljAELvGmJAcNUpeKUg4VXHarVjoOp31ysNjazOZsYwOKAMqKGWedYYI2kllIVVUZJP0r6M+D/wbFgYNY8VIGuPvxWh6L6Fv8K6T4QfC2z8K2kWpanGlxrDjcpYZEI9vevUyTjOc0AAGFAAwAMAAYAFApeKSgApUBJpKdH1oAZuVuVORRWXHK8bfumyvoau21yJshlKv6GgCxRQaKACiijvQADrXMeN/BumeK7Jku4Y1uR9yUDBz6GunoFAHyJ4x+GmraJfSCOJniHKnqCK4gWl5ZyZeOQMD6dK+5dTsUvowsh4HTIziuSvvBun3ErLNbxnPfb1oA+Pb9p7hmkkDlj7VPoizwzhogxY8cV9Xy/C3RrqEB4UTHtU2nfDDQrR1KR5K89KAPBF8D3uoxLcQglmGSCK6PSfhfLLboLuMg55r3uHTrSyZY0twUHoKnu181QsEOB6gUAcB4d8F6bpCKAgEg74rtrHTS6AhVVO3FLZ6dI1x+/BUCt0LtGBwBQBDbWsVuP3ajPc1PRRQAUUUdqACiiigA70UUUAFJS0UAU9V02z1axks9Rt0uLdxyjjOPceh96+eviz8L7jRidR0W2a608feVRlovqO496+ke1GOD9MH6UAfCd0hMKMUZWzgJjpTUtEihaRiFm7J6V9eeKPh1oWvxSsLZLO7YHEsS4GfcV4N4v+E/iTRLh3t7Q6jbY4mt/mJHuOtAHnlsZ5bhM/MAMAioZI3QB1kJTdztOMH3q7dW+oWrKJ7eW3aM4wyFarlf8AXKGwr/NtPrQBHNKZ3UE7P7zVcsdR8lXtBGGtpF545z61QihYqOefp1qVLW4d98cMrdsBTQAkTy2jiWEByCcoehqK5IaQyCPYG52Zziui0XwVrmsyqtvaT7TxuYEDFeweDvggkLJc63KrtwfLB4oA8W8L+ENS8SXCpZ27rFn5pCDgfSvqnwF4OtvDmkWovG825Tpu7H+tdLo+jWWj24hsYEQD+LHNXiilw7ICw6E9qAHHrzmig0UAFFFFABSrimsQOpAFVZtQihPB3fSgDKWZN3zAqasLOPkJ5Fcp4Q1+PxN4es9Xhj8tbhc7D/Ce4reQtj5TxQBtJcEkY+7VoEEZBrCD7xgE7hU1pdsH2HsaANiikByAaWgAooooABRQKMZoAOKKOlNkcRoWPagB2B6D8qQADgUKcgH1pcigBKXtS44zSdaAD+dFFJkZx3oAUUfyoooABSAg0tIFVeFGKAFooo9fSgAoo6c0UAH1oo7UnfOTQAtAJB4JFFGc0AV7uytL1SLy0tpx/wBNIw1Ydz4F8LXLlptDsyx6lVxXSfzpM84zzQBzCfD/AMKJymiWowexNaVt4c0a2Ui20y2j+i1rA8e1A5FAEUFvDbptgiSNf9kVL+FA/nRQAUmc9D0o4OQKAMdKAFzhfWkzR2pJGCIWNAAzquckDFVZb1VyEBJFVnjRpS7uxyegoudqKNtAETyTTuS7YXsK5Hxp430fwgYRqkw3zEgIp5HvWtr2tLpWk3l6wytvEXPHPFfCXxC8WXvi3xFcX925ALEImeFHpQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of the chest showing bilateral, diffuse areas of ground glass opacities in the midlung zones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E. King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12480=[""].join("\n");
var outline_f12_12_12480=null;
var title_f12_12_12481="Waist circumference PI";
var content_f12_12_12481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    How to measure your waist circumference",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To measure your waist circumference, place the measuring tape around your belly just above your hipbone. Make sure the measuring tape is snug but not too tight. Also, make sure the tape measure is parallel to the floor as it circles your body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart Lung and Blood Institute, Bethesda MD, October 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12481=[""].join("\n");
var outline_f12_12_12481=null;
var title_f12_12_12482="Molluscum face 2";
var content_f12_12_12482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple dome-shaped papules with a central core are present on the face of this child with molluscum contagiosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12482=[""].join("\n");
var outline_f12_12_12482=null;
var title_f12_12_12483="Patient information: What you should know about antibiotics (The Basics)";
var content_f12_12_12483=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/84035\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"         Hives",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/47/31473\">",
"         Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/19/39217\">",
"         Patient information: Vancomycin-resistant enterococci (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/37/22098\">",
"         Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/4/22595\">",
"         Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: What you should know about antibiotics (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/what-you-should-know-about-antibiotics-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H179433786\">",
"      <span class=\"h1\">",
"       What are antibiotics?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Antibiotics are medicines that help people fight infections caused by bacteria. They work by killing bacteria that are in the body. These medicines come in many different forms, including pills, ointments, and liquids that are given by injection.",
"     </p>",
"     <p>",
"      Antibiotics can do a lot of good. For people with serious bacterial infections, antibiotics can save lives. But people use them far too often, even when they're not needed. This is causing a very serious problem called antibiotic resistance. Antibiotic resistance happens when bacteria that have been exposed to an antibiotic change so that the antibiotic can no longer kill them. In those bacteria, the antibiotic has no effect. Because of this problem, doctors are having a harder and harder time treating infections. Experts worry that there will soon be infections that don't respond to any antibiotics.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179433801\">",
"      <span class=\"h1\">",
"       When are antibiotics helpful?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Antibiotics can help people fight off infections caused by bacteria. They",
"      <strong>",
"       DO NOT",
"      </strong>",
"      work on infections caused by viruses.",
"     </p>",
"     <p>",
"      Some common bacterial infections that are treated with antibiotics include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Strep throat",
"       </li>",
"       <li>",
"        Pneumonia (an infection of the lungs)",
"       </li>",
"       <li>",
"        Bladder infections",
"       </li>",
"       <li>",
"        Infections you catch through sex, such as gonorrhea and chlamydia",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179433816\">",
"      <span class=\"h1\">",
"       When are antibiotics NOT helpful?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Antibiotics do not work on infections caused by viruses.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics are",
"        <strong>",
"         NOT",
"        </strong>",
"        helpful for the common cold, because the common cold is caused by a virus.",
"       </li>",
"       <li>",
"        Antibiotics are",
"        <strong>",
"         NOT",
"        </strong>",
"        helpful for the flu, because the flu is caused by a virus. (People with the flu can be treated with medicines called antiviral medicines, which are different from antibiotics.)",
"       </li>",
"       <li>",
"        Antibiotics are",
"        <strong>",
"         NOT",
"        </strong>",
"        helpful for most cases of sore throat, because sore throat is usually caused by a virus. (Strep throat is an exception.)",
"       </li>",
"       <li>",
"        Antibiotics are",
"        <strong>",
"         NOT",
"        </strong>",
"        helpful for most cases of sinusitis, because sinusitis is usually caused by a virus. Sinusitis that starts out as a viral infection can turn into a bacterial infection, but that takes time. If you have had sinusitis symptoms for less than 10 days, you should not take antibiotics unless you also have a high fever.",
"       </li>",
"       <li>",
"        Antibiotics are",
"        <strong>",
"         NOT",
"        </strong>",
"        helpful for most cases of acute bronchitis (an infection in the airways leading to the lungs), because bronchitis is usually caused by a virus. If you have bronchitis and cough up green mucus, that does NOT mean you have a bacterial infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Even though antibiotics don't work on infections caused by viruses, people sometimes believe that they do. That's because they took antibiotics for a viral infection before and then got better. The problem is that those people would have gotten better with or without an antibiotic. When they get better with the antibiotic, they think that&rsquo;s what cured them, when in reality the antibiotic had nothing to do with it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179433831\">",
"      <span class=\"h1\">",
"       What&rsquo;s the harm in taking antibiotics even if they might not help?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many reasons you should not take antibiotics unless you absolutely need them:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Antibiotics cause side effects",
"        </strong>",
"        , such as nausea, vomiting, and diarrhea. They can even make it more likely that you will get a different kind of infection, such as yeast infection (if you are woman).",
"       </li>",
"       <li>",
"        <strong>",
"         Allergies to antibiotics are common.",
"        </strong>",
"        You can develop an allergy to an antibiotic, even if you have not had a problem with it before. Some allergies are just unpleasant, causing rashes and itching. But some can be very serious and even life-threatening. It is better to avoid any risk of an allergy, if the antibiotic wouldn&rsquo;t help you anyway.",
"       </li>",
"       <li>",
"        <strong>",
"         Overuse of antibiotics leads to antibiotic resistance.",
"        </strong>",
"        Using antibiotics when they are not needed gives bacteria a chance to change, so that the antibiotics cannot hurt them later on. People who have infections caused by antibiotic-resistant bacteria often have to be treated in the hospital with many different antibiotics. People can even die from these infections, because there is no antibiotic that will cure them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179433846\">",
"      <span class=\"h1\">",
"       When should I take antibiotics?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should take antibiotics only when a doctor or nurse prescribes them to you. You should never take antibiotics prescribed to someone else, and you should not take antibiotics that were prescribed to you for a previous illness. When prescribing an antibiotic, doctors and nurses have to carefully pick the right antibiotic for a particular infection. Not all antibiotics work on all bacteria.",
"     </p>",
"     <p>",
"      If you do have an infection caused by a bacteria, your doctor or nurse might want to find out what that bacteria is, and which antibiotics can kill it. They do this by taking a &ldquo;culture&rdquo; of the bacteria and growing it in the lab. But it&rsquo;s not possible to do a culture on someone who has already started an antibiotic. So if you start an antibiotic without input from a doctor or nurse it will be impossible to know if you have taken the right one.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179433861\">",
"      <span class=\"h1\">",
"       What can I do to reduce antibiotic resistance?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Here are some things that can help:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Do not pressure your doctor or nurse for antibiotics when he or she does not think you need them.",
"       </li>",
"       <li>",
"        If you are prescribed antibiotics, finish all of the medicine and take it exactly as directed. Never skip doses or stop taking the medicine without talking to your doctor or nurse.",
"       </li>",
"       <li>",
"        Do not give antibiotics that were prescribed to you to anyone else.",
"       </li>",
"       <li>",
"        Do not use antibacterial soaps or cleaning products. (Alcohol-based hand gels are fine to use.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179433876\">",
"      <span class=\"h1\">",
"       What if my doctor prescribes an antibiotic that did not work for me before?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If an antibiotic did not work for you before, that does not mean it will never work for you. If you have used an antibiotic before and it did not work, tell your doctor. But keep in mind that the infection you had before might not have been caused by the same bacteria that you have now. The &ldquo;best&rdquo; antibiotic is the right 1 for the bacteria causing the infection, not for the person with the infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179433893\">",
"      <span class=\"h1\">",
"       What if I am allergic to an antibiotic?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you had a bad reaction to an antibiotic, tell your doctor or nurse about it. But do not assume you are allergic unless your doctor or nurse tells you that you are.",
"     </p>",
"     <p>",
"      Many people who think they are allergic to an antibiotic are wrong. If you get nauseous after taking an antibiotic, that does NOT mean you are allergic to it. Nausea is a common side effect of many antibiotics. If you are a woman and you get a yeast infection after taking an antibiotic, that does",
"      <strong>",
"       NOT",
"      </strong>",
"      mean you are allergic to it. Yeast infections are a common side effect of antibiotics.",
"     </p>",
"     <p>",
"      Symptoms of antibiotic allergy can be mild and include a flat rash and itching. They can also be more serious and include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hives &ndash; Hives are raised, red patches of skin that are usually very itchy (",
"        <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Lip or tongue swelling",
"       </li>",
"       <li>",
"        Trouble swallowing or breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Serious allergy symptoms can start right after you start taking an antibiotic if you are very sensitive. Less serious symptoms, on the other hand, often start a day or more later.",
"     </p>",
"     <p>",
"      If you think you are allergic to antibiotics, tell your doctor or nurse why you think so. Then trust him or her to know whether what you describe is a true allergy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H179433908\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/47/31473?source=see_link\">",
"       Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/19/39217?source=see_link\">",
"       Patient information: Vancomycin-resistant enterococci (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=see_link\">",
"       Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"       Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/12/12483?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 84035 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12483=[""].join("\n");
var outline_f12_12_12483=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433786\">",
"      What are antibiotics?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433801\">",
"      When are antibiotics helpful?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433816\">",
"      When are antibiotics NOT helpful?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433831\">",
"      What&rsquo;s the harm in taking antibiotics even if they might not help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433846\">",
"      When should I take antibiotics?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433861\">",
"      What can I do to reduce antibiotic resistance?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433876\">",
"      What if my doctor prescribes an antibiotic that did not work for me before?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433893\">",
"      What if I am allergic to an antibiotic?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179433908\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/84035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"      Hives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=related_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/47/31473?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/19/39217?source=related_link\">",
"      Patient information: Vancomycin-resistant enterococci (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_12_12484="Plasma exchange in the hyperviscosity syndrome due to immunoglobulins";
var content_f12_12_12484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Plasma exchange in the hyperviscosity syndrome due to immunoglobulins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12484/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12484/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12484/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12484/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12484/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12484/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/12/12484/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperviscosity syndrome results from high levels of proteins capable of increasing the serum viscosity. Classically, the syndrome is a result of increased amounts of IgM, as seen in Waldenstrom macroglobulinemia; however, hyperviscosity has also been described in certain cases of multiple myeloma in which abnormal polymers of IgA, IgG, or kappa light chains are produced [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of plasma exchange in the hyperviscosity syndrome due to immunoglobulins will be discussed here. The diagnosis and treatment of patients with Waldenstrom macroglobulinemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=see_link\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9804211\">",
"    <span class=\"h1\">",
"     SIGNS AND SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperviscosity can lead to impairment in the microcirculation of the central nervous system, possibly resulting in headache, dizziness, vertigo, nystagmus, hearing loss, visual impairment, somnolence, coma, and seizures. Other possible findings include mucosal hemorrhage due to reduced platelet function, heart failure, which has been attributed to an expanded plasma volume (see below), renal failure, and sausage-like beading in the retinal veins (",
"    <a class=\"graphic graphic_picture graphicRef50216 \" href=\"UTD.htm?20/45/21215\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9804543\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is established by measuring serum viscosity, most frequently via the use of an Ostwald viscosimeter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/5\">",
"     5",
"    </a>",
"    ]. Normal serum viscosity is between 1.4 and 1.8 (measured as the flow time through the viscometer of the patient's serum divided by that of water or saline). Patients with values between 2 and 4 are only rarely symptomatic, while symptoms occur in most patients with values between 5 and 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/1\">",
"     1",
"    </a>",
"    ]. Values above 10 are invariably associated with symptoms. Corresponding values of IgM are commonly between 4 and 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    but the correlation with viscosity values is not linear [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/6\">",
"     6",
"    </a>",
"    ]. Total serum protein levels usually exceed 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Overview'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2213249#H2213249\">",
"     \"Recognition of monoclonal proteins\", section on 'Serum viscosity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF PLASMA EXCHANGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with severe neurologic impairment, such as stupor or coma, should be treated with plasma exchange (plasmapheresis) on an emergency basis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/1,6-9\">",
"     1,6-9",
"    </a>",
"    ]. A reasonable initial prescription would be a one plasma volume exchange (see below), replaced with albumin, repeated daily until symptoms subside or until serum viscosity is normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five to 20 liters of exchanged plasma may be required for IgM related disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgA or IgG related syndromes may require a greater volume and a more repetitive treatment schedule, since a larger percentage of these smaller immunoglobulins are extravascular. As a result, lowering of serum values will be followed by extravascular to intravascular redistribution [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/10-12\">",
"       10-12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cascade filtration, with on-line separation of the large molecular weight polymers with a \"secondary\" filter, can limit the need for replacement fluid. Secondary filters are increasingly difficult to obtain in the United States, but are generally available in Europe and Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperviscosity syndromes are likely to increase the plasma volume beyond that calculated by commonly used formulas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. In one patient, for example, we were able to document a plasma volume of 6.7 liters using isotopically labeled albumin when the calculated value was only 4 liters [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms should subside with the lowering of serum viscosity. However, irreversible changes can occur, such as irreversible hearing loss that is presumably due to venous thrombosis of the inner ear [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasmapheresis does not affect the disease process. Thus, cessation of plasma exchange treatments, in the absence of other therapy, will result in a recurrence of symptoms within two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12484/abstract/1\">",
"     1",
"    </a>",
"    ]. It is therefore important that chemotherapy directed toward the underlying dysglobulinemia be instituted as soon as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9804309\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperviscosity syndrome results from high levels of proteins, usually IgM in patients with Waldenstrom macroglobulinemia, capable of increasing the serum viscosity. However, it has also been described in multiple myeloma in which abnormal polymers of IgA, IgG, or kappa light chains are produced.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperviscosity can lead to impairment in the microcirculation of the central nervous system, resulting in headache, dizziness, vertigo, nystagmus, hearing loss, visual impairment, somnolence, coma, and seizures. Other possible findings include mucosal hemorrhage renal failure, and sausage-like beading in the retinal veins (",
"      <a class=\"graphic graphic_picture graphicRef50216 \" href=\"UTD.htm?20/45/21215\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9804211\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is established by measuring serum viscosity, most frequently via the use of an Ostwald viscosimeter. Normal serum viscosity is between 1.4 and 1.8. Symptoms occur in most patients with values between 5 and 8. (See",
"      <a class=\"local\" href=\"#H9804543\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients presenting with severe neurologic impairment, such as stupor or coma, should be treated with plasma exchange (plasmapheresis) on an emergency basis. A reasonable initial prescription would be a one plasma volume exchange, replaced with albumin, repeated daily until symptoms subside or until serum viscosity is normal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Role of plasma exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since plasmapheresis does not affect the disease process, chemotherapy directed against the underlying disease should be instituted at the same time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Initial treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/1\">",
"      Bloch KJ, Maki DG. Hyperviscosity syndromes associated with immunoglobulin abnormalities. Semin Hematol 1973; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/2\">",
"      Carter PW, Cohen HJ, Crawford J. Hyperviscosity syndrome in association with kappa light chain myeloma. Am J Med 1989; 86:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/3\">",
"      Bachrach HJ, Myers JB, Bartholomew WR. A unique case of kappa light-chain disease associated with cryoglobulinemia, pyroglobulinemia, and hyperviscosity syndrome. Am J Med 1989; 86:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/4\">",
"      Kes P, Pecani Z, Getaldi B, Ratkovi-Gusi I. Treatment of hyperviscosity syndrome in the patients with plasma cell dyscrasias. Acta Med Croatica 1996; 50:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/5\">",
"      Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012; 119:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/6\">",
"      SOLOMON A, FAHEY JL. Plasmapheresis therapy in macroglobulinemia. Ann Intern Med 1963; 58:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/7\">",
"      Current status of therapeutic plasmapheresis and related techniques. Report of the AMA panel on therapeutic plasmapheresis. Council on Scientific Affairs. JAMA 1985; 253:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/8\">",
"      Isbister JP, Biggs JC, Penny R. Experience with large volume plasmapheresis in malignant paraproteinaemia and immune disorders. Aust N Z J Med 1978; 8:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/9\">",
"      Drew MJ. Plasmapheresis in the dysproteinemias. Ther Apher 2002; 6:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/10\">",
"      BARTH WF, WOCHNER RD, WALDMANN TA, FAHEY JL. METABOLISM OF HUMAN GAMMA MACROGLOBULINS. J Clin Invest 1964; 43:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/11\">",
"      COHEN S, FREEMAN T. Metabolic heterogeneity of human gamma-globulin. Biochem J 1960; 76:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/12\">",
"      Kaplan AA. Towards a rational prescription of plasma exchange: The kinetics of immunoglobulin removal. Semin Dial 1992; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/13\">",
"      Valbonesi M, Mosconi L, Montani F, et al. Cascade filtration: clinical application in 26 patients with immune complex and IgM mediated diseases. Int J Artif Organs 1983; 6:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/14\">",
"      Alexanian R. Blood volume in monoclonal gammopathy. Blood 1977; 49:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12484/abstract/15\">",
"      Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int 1990; 38:160.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6651 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12484=[""].join("\n");
var outline_f12_12_12484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9804309\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9804211\">",
"      SIGNS AND SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9804543\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF PLASMA EXCHANGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9804309\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6651\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6651|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/45/21215\" title=\"picture 1\">",
"      Retinopathy in WM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=related_link\">",
"      Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_12_12485="Nelarabine: Patient drug information";
var content_f12_12_12485=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nelarabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=see_link\">",
"     see \"Nelarabine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/19/20789?source=see_link\">",
"     see \"Nelarabine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1987961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arranon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5505580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atriance&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad nervous system problems including great sleepiness, seizures, weakness, or numbness or tingling of the feet or hands. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nelarabine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bruising.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698645",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble walking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble doing actions such as doing up buttons or zippers or opening tops of products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11562 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12485=[""].join("\n");
var outline_f12_12_12485=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987961\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505580\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030802\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030804\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030803\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030808\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030809\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030811\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030806\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030813\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=related_link\">",
"      Nelarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/19/20789?source=related_link\">",
"      Nelarabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_12_12486="Azilsartan and chlorthalidone: Drug information";
var content_f12_12_12486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azilsartan and chlorthalidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/24/32133?source=see_link\">",
"    see \"Azilsartan and chlorthalidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13740969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13772304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      edarbyclor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13655306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13741060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose is individualized; combination product may be substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within the same antihypertensive class). May also be used as initial therapy in patients who are likely to need &gt;1 antihypertensive to control blood pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"     <i>",
"      Initial therapy:",
"     </i>",
"     Azilsartan 40 mg/chlorthalidone 12.5 mg once daily; dose may be increased after 2-4 weeks of therapy to azilsartan 40 mg/chlorthalidone 25 mg once daily. Maximum recommended dose: Azilsartan 40 mg/day; chlorthalidone 25 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13741061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13741063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate renal impairment (eGFR 30-90 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe renal impairment (eGFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): Safety and effectiveness not established.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13741062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hepatic impairment: No initial dosage adjustment necessary; monitor patient carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment: Safety and effectiveness not established; use with caution in patients with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13741155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     edarbyclor&trade;: 40/12.5: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     edarbyclor&trade;: 40/25: Azilsartan medoxomil 40 mg and chlorthalidone 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13740971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13741143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13655308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13740986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (9%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Serum creatinine increased (2%), BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13740976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13740977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur in patients taking angiotensin II receptor blockers; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur with chlorthalidone. Incidence of chlorthalidone-associated hypokalemia is reduced when given as a combination with azilsartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with azilsartan/chlorthalidone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur with chlorthalidone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure, volume depletion) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use of chlorthalidone in patients with thiazide or sulfonamide allergy is specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use azilsartan with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use chlorthalidone with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated with chlorthalidone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use chlorthalidone with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: Thiazide diuretics (eg, chlorthalidone) may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use chlorthalidone with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use chlorthalidone with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use azilsartan with caution in pre-existing renal insufficiency and severe renal impairment. Avoid chlorthalidone in severe renal disease (ineffective); contraindicated in patients with anuria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Chlorthalidone can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13768995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13768993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13893538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13740973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13740974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13740975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chlorthalidone can be detected in breast milk. It is not known if azilsartan is excreted into breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13741142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Edarbyclor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-12.5 mg (30): $109.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-25 mg (30): $109.60",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13740990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azilsartan: Angiotensin II (which is formed by enzymatic conversion from angiotensin I) is the primary pressor agent of the renin-angiotensin system. Effects of angiotensin II include vasoconstriction, stimulation of aldosterone synthesis/release, cardiac stimulation, and renal sodium reabsorption. Azilsartan inhibits angiotensin II&rsquo;s vasoconstrictor and aldosterone-secreting effects by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and adrenal gland tissues (azilsartan has a stronger affinity for the AT1 receptor than the AT2 receptor). The action is independent of the angiotensin II synthesis pathways. Azilsartan does not inhibit ACE (kininase II), therefore it does not affect the response to bradykinin (the clinical relevance of this is unknown) and does not bind to or inhibit other receptors or ion channels of importance in cardiovascular regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chlorthalidone: A sulfonamide-derived diuretic that inhibits sodium and chloride reabsorption in the cortical-diluting segment of the ascending loop of Henle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13740992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17102 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12486=[""].join("\n");
var outline_f12_12_12486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740969\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13772304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655306\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13741060\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13741061\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13741063\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13741062\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13741155\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740971\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13741143\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655308\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740986\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740976\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740977\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768995\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768993\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13893538\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740973\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740974\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740975\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13741142\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322926\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740990\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13740992\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/24/32133?source=related_link\">",
"      Azilsartan and chlorthalidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_12_12487="Follicular large cell NHL";
var content_f12_12_12487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular lymphoma grade III (follicular large cell lymphoma)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This field is predominated by large noncleaved cells (centroblasts) which vary in size.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12487=[""].join("\n");
var outline_f12_12_12487=null;
var title_f12_12_12488="RNS in myasthenia gravis";
var content_f12_12_12488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repetitive nerve stimulation pre and post exercise in a patient with myasthenia gravis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 687px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stimulating the ulnar nerve at the wrist, recording the first dorsal interosseous. Maximal decrement noted to the right of traces.",
"    <br>",
"     (A) Baseline",
"     <br>",
"      (B) Immediately after 10 seconds of exercise (postexercise facilitation)",
"      <br>",
"       (C, D) Two and three minutes after 60 seconds of exercise (postexercise exhaustion)",
"       <br>",
"        (E) Immediately after 10 seconds of exercise again (postexercise facilitation and repair of the decrement)",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced from: Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, 2nd edition, Butterworth-Heinemann, 2005. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12488=[""].join("\n");
var outline_f12_12_12488=null;
var title_f12_12_12489="Radiologic evaluation of the acutely painful knee in adults";
var content_f12_12_12489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiologic evaluation of the acutely painful knee in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12489/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12489/contributors\">",
"     Shahla Modarresi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12489/contributors\">",
"     Cecilia M Jude, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12489/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12489/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12489/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12489/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/12/12489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee is one of the largest and most complex joints in the body. It is lined by synovium and consists of two hinge-type joints between the femoral condyles and the medial and lateral tibial plateaus and of a gliding-type joint between the patella and the trochlear groove of the anterior distal femur (",
"    <a class=\"graphic graphic_figure graphicRef69611 \" href=\"UTD.htm?34/27/35251\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/1\">",
"     1",
"    </a>",
"    ]. The major stabilizers of the joint are the extensor tendons (quadriceps and patellar tendons), the medial and lateral collateral ligament complex, and the cruciate ligaments. The menisci are fibrocartilaginous structures that distribute the stress over the articular cartilage, that absorb the shock in axial loading, that stabilize the joint in flexion and extension, and that have a role in joint lubrication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging modalities used to evaluate adults with acute knee pain and the appropriateness of particular imaging studies in different clinical scenarios will be reviewed here. The history and physical examination, which are necessary to develop a differential diagnosis prior to the selection of imaging tests, as well as a general review of imaging tests that are used in the evaluation of bone and joint pain, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=see_link\">",
"     \"Diagnostic imaging of joint pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic knee pain is commonly caused by arthritis, bursitis, and cystic lesions around the joint; tendon pathology; cartilage pathology; chronic infection; osteonecrosis (avascular necrosis); stress fractures; and avulsion injuries.",
"   </p>",
"   <p>",
"    The use of imaging in the assessment of children and adolescents with knee pain is also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"     \"Approach to the young athlete with chronic knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee is vulnerable to direct trauma. Most acute injuries sustained during adolescence and adulthood are caused by athletic activities, motor vehicle accidents, or falls. The most common injuries involve the soft tissues, including ligaments, cartilage, and menisci. Knee fractures are more common than dislocations. Radiological evaluation plays a major role in the diagnosis of knee injuries.",
"   </p>",
"   <p>",
"    The Ottawa knee rule uses a set of criteria based upon patient age, the presence of local tenderness, limited range of motion, and inability to bear weight. The Ottawa knee rule has a high sensitivity for fractures in the region of the knee but has limited specificity. The Ottawa knee rule is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link&amp;anchor=H51#H51\">",
"     \"Evaluation of the active adult patient with knee pain\", section on 'Knee trauma and Ottawa knee rule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When imaging is indicated, acute knee trauma is initially evaluated with plain film radiographs. Patients with a history of trauma, for whom there is a high clinical suspicion of fracture or soft tissue injury that is not apparent on plain radiographs, should be further assessed with computed tomography (CT) or with magnetic resonance imaging (MRI) based upon the type of injury suspected. Suspected soft tissue injuries involving the cartilage, menisci, ligaments, and tendons are best evaluated by MRI. CT arthrography with intraarticular iodinated contrast may be used in cases when MRI is contraindicated (eg, metallic foreign body around the knee, pacemaker, aneurysm clip).",
"   </p>",
"   <p>",
"    The role of each imaging modality in evaluation of knee trauma is detailed below. Categories of trauma highlighted include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bone injuries",
"     </li>",
"     <li>",
"      Chondral and osteochondral injuries",
"     </li>",
"     <li>",
"      Soft tissue injuries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last category, soft tissue injuries, includes partial and complete tears of the menisci, tendons, ligaments, and muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bone injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography is the initial study of choice for trauma or suspected fracture involving the knee. However, the high incidence of soft tissue injuries with or without associated fractures often requires additional cross-sectional imaging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Most fractures of the knee, avulsion injuries, and dislocations will be identified on plain film. The standard initial examination includes anteroposterior and lateral projections. If the patient is unable to stand, a cross table lateral view should be obtained instead of a standing lateral view. Either the cross table or the standing lateral view may allow a fat fluid level to be identified, a radiographic finding indicative of an intraarticular fracture that might otherwise not be apparent on plain films. The tunnel projection is indicated for suspected fracture of the posterior aspect of the distal femur.",
"      <br/>",
"      <br/>",
"      Fracture of the patella is common after acute knee injury. If patellar injury is suspected, a sunrise (axial) view of the patella should also be obtained (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61607 \" href=\"UTD.htm?12/35/12863\">",
"       image 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Certain fractures are known to be associated with ligament and meniscal tears, requiring further evaluation by MRI. Examples of such fractures include Segond fracture (avulsion fracture of the lateral tibial condyle) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59493 \" href=\"UTD.htm?41/21/42334\">",
"       image 2",
"      </a>",
"      ), fracture of the tibial spine (avulsion fracture of the intercondylar eminence by the cruciate ligaments) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62929 \" href=\"UTD.htm?32/61/33759\">",
"       image 3",
"      </a>",
"      ), fibular head avulsion fracture, and posteromedial tibial plateau fracture.",
"      <br/>",
"      <br/>",
"      Radiographically occult bone injuries include tibial plateau and tibial spine fractures, transient dislocation of the patella, and bone bruises. Tibial plateau fractures may not be obvious on routine radiographs, particularly when there is no depression in the tibial plateau, and may only be detected on the cross table lateral view. As noted above, the presence of a fat fluid level in the cross table lateral or standing lateral view is indicative of an intraarticular fracture (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57191 \" href=\"UTD.htm?28/2/28718\">",
"       image 4",
"      </a>",
"      ) and should be further investigated by CT scan. All other suspected radiographically occult fractures that do not involve the joint should be further investigated by MRI, which is more sensitive for non-cortical fractures and for bone marrow edema due to bone bruise.",
"     </li>",
"     <li>",
"      CT &mdash; CT is indicated in patients with a history of trauma for whom there is a high clinical suspicion of fracture involving the knee joint not apparent on plain radiographs. Multidetector CT (MDCT) is also recommended in evaluation of all tibial plateau fractures and complex osseous knee injuries. In one study, 409 patients with acute traumatic knee injuries caused by motor vehicle accidents, falls, or sports were evaluated with both plain film and MDCT [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/3\">",
"       3",
"      </a>",
"      ]. This group had an overall rate of fractures of 87 percent. Plain radiographs were falsely negative for the detection of knee fractures in 30 percent of patients, and 70 percent of fracture cases were better characterized by MDCT than by plain film radiography [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/3\">",
"       3",
"      </a>",
"      ]. Part of the difference in sensitivity may be explained by the difficulty in optimally positioning severely injured patients for plain radiographs.",
"      <br/>",
"      <br/>",
"      CT demonstrates the position of fracture fragments and the intraarticular extension of fracture and quantifies the extent of the depression in tibial plateau fractures. Three-dimensional reformations are useful in visualization of complex fractures and in surgical planning [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. CT also evaluates nonunion fractures, underlying pathological bone and secondary infection [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI &mdash; MRI is more sensitive than CT in depicting non-displaced trabecular fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/7\">",
"       7",
"      </a>",
"      ]. MRI is the procedure of choice for detection of radiographically occult trabecular fractures and bone bruise.",
"      <br/>",
"      <br/>",
"      Although CT delineates complex tibial plateau fractures better than MRI and is the imaging procedure of choice for preoperative planning, MRI can also be used in cases of radiation exposure concern (eg, pregnancy) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/8\">",
"       8",
"      </a>",
"      ]. MRI can detect associated ligamentous and meniscal injuries in cases of tibial plateau fractures, the presence of which may alter management. For example, nondisplaced fractures of the tibial plateau without associated ligamentous injuries can be treated conservatively.",
"      <br/>",
"      <br/>",
"      As noted above, MRI is also indicated in the presence of Segond fracture, a small avulsion fracture of the lateral tibial condyle that is highly associated with anterior cruciate ligament (ACL) and lateral meniscus tears and which can result in chronic knee instability.",
"      <br/>",
"      <br/>",
"      MRI is indicated in the presence of a fibular head avulsion fracture, which can be associated with posterior cruciate ligament (PCL) tears and avulsion of the arcuate complex, resulting in posterior lateral instability.",
"      <br/>",
"      <br/>",
"      MRI is valuable in diagnosing transient dislocation of the patella, which shows a typical bone contusion pattern from impaction of the medial side of the patella on the anterolateral femoral condyle. MRI can also show the relationship between the patella and the femoral trochlea and evidence of patellofemoral maltracking as a risk factor for patellar subluxation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/9\">",
"       9",
"      </a>",
"      ]. MRI can also demonstrate the highly associated tear of the medial patellar retinaculum and cartilage injury, which usually requires arthroscopic surgery.",
"     </li>",
"     <li>",
"      Radionuclide scan &mdash; Radionuclide bone scan is indicated in cases with suspected fracture and negative radiographs when MRI or CT is not available.",
"     </li>",
"     <li>",
"      Angiography &mdash; Angiography is indicated if associated vascular injury is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute chondral and osteochondral injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondral and chondral fractures usually result from athletic activities or direct trauma. The most common injuries in the skeletally immature knee are chondral fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/10\">",
"     10",
"    </a>",
"    ]. Loss of the ability to move the knee smoothly, the presence of a trauma-induced knee effusion, or physical findings suggestive of an associated soft tissue injury (eg, cruciate ligament or meniscal tear) suggest the presence of a chondral fracture or osteochondral injury that is best evaluated by MRI. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Soft tissue injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Chondral fractures are not visualized on plain radiography, since they only involve the articular cartilage, and should be evaluated by MRI. Osteochondral fractures may be detected on plain films, especially if the fragment is displaced in the knee joint.",
"     </li>",
"     <li>",
"      MR imaging and MR arthrography &mdash; MRI should be performed in all suspected cases of chondral and osteochondral injuries. With arthroscopic assessment as the gold standard, MRI accuracy for detecting articular cartilage defect is greater than 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/11\">",
"       11",
"      </a>",
"      ]. MRI demonstrates chondral and osteochondral fractures and osteochondral loose bodies. Focal subchondral edema is commonly associated with full thickness articular cartilage defect and is a marker of cartilage injury [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/12\">",
"       12",
"      </a>",
"      ]. MR arthrography is indicated in assessing the stability of the osteochondral fragment. If separation of the osteochondral fragment is present, surgical intervention may be necessary. When compared with arthroscopic findings, MRI is sensitive and specific in the qualitative and quantitative follow-up of cartilage repair after treatment of full thickness chondral defects [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and CT arthrography &mdash; CT detects osteochondral injuries by identifying a loose intraarticular body and defect of the articular surface.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Soft tissue injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue injuries include knee joint capsule, meniscal, ligamentous, tendon, and muscle injuries. Plain film radiography is limited in the evaluation of extent of soft tissue injuries; however, according to the American College of Radiology Appropriateness Criteria, initial evaluation of any cause of knee pain should start with a plain film radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/14\">",
"     14",
"    </a>",
"    ]. Joint effusion, soft tissue swelling, soft tissue foreign body, and avulsion injuries can be easily detected.",
"   </p>",
"   <p>",
"    MRI is indicated in patients with a history of trauma for whom there is a high clinical suspicion of soft tissue injury, the presence of which, if confirmed, would alter medical management or would warrant surgical intervention. MRI is the procedure of choice for evaluating the menisci, ligaments, and tendons. In addition, MRI detects joint effusions, muscle tears, and hematomas. CT is not optimal for evaluation of the soft tissue, tendons, and ligaments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Knee joint effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography is adequate to detect clinically significant traumatic knee effusion. However, a knee injury sufficient to cause an effusion often causes bone or soft tissue injuries as well [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. As an example, among 114 patients with traumatic knee injury who had plain radiographs that only demonstrated an effusion and whose physical examination revealed no clinically apparent ligamentous injury (ie, who had &ldquo;stable knees&rdquo;), further investigation with MRI revealed 144 abnormalities, including bone injury (53 percent), disruption of the anterior cruciate ligament (19 percent), sprain of the medial collateral ligament (12 percent), tear of the medial or lateral meniscus (11 and 5 percent, respectively), or, less often, rupture of the posterior cruciate ligament (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Knee joint effusion is demonstrated on the lateral radiograph as an oval-shaped density obscuring the suprapatellar fat pad (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52601 \" href=\"UTD.htm?35/49/36638\">",
"       image 5",
"      </a>",
"      ). Although no further imaging is needed for detection of an effusion per se, a cross table lateral or a standing lateral view may identify a fat fluid level in cases of lipohemarthrosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57191 \" href=\"UTD.htm?28/2/28718\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ultrasound &mdash; Ultrasound is sensitive for detection of joint effusion. In the setting of acute trauma, ultrasound can detect lipohemarthrosis, which is a sign of intraarticular extension of fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/17\">",
"       17",
"      </a>",
"      ]. The role of ultrasonography in the assessment of the acutely injured knee has not been established. Clinical studies comparing the characteristics of this imaging modality with those of MRI are needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Meniscal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, meniscal injuries often accompany serious knee injuries and are well-known to occur in association with certain ligamentous injuries (eg, medial meniscal tear and anterior cruciate ligament and medial collateral ligament tears).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; The menisci are not visualized on plain radiography; however, considerable narrowing of the joint space seen in severe degenerative joint disease is an indirect sign of chronic meniscal tear.",
"     </li>",
"     <li>",
"      MRI and MR arthrography &mdash; MRI is the procedure of choice for evaluating the menisci, ligaments, and tendons. When compared with arthroscopic findings, the sensitivity and specificity of MRI for diagnosis of meniscal tears range from 90 to 95 percent and 90 to 98 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Several studies performed with higher field 3 Tesla MRI demonstrate sensitivity and specificity of 96 to 97 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/20\">",
"       20",
"      </a>",
"      ]. Tears of the medial meniscus are common sports-related injuries. Tears of the lateral meniscus are less common. Lateral meniscal tears are commonly associated with discoid meniscus, a developmental anomaly.",
"      <br/>",
"      <br/>",
"      MRI demonstrates the spectrum of meniscal pathology, from myxoid degeneration to complete tear. Horizontal or oblique meniscal tears are frequently seen in both symptomatic and asymptomatic knees, and the prevalence of MRI-detected tears in asymptomatic knees increases markedly with age (from 13 percent in individuals under age 45 years to 36 percent in older individuals) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, radial, vertical, complex, or displaced meniscal tears are almost always associated with knee pain [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/22\">",
"       22",
"      </a>",
"      ]. Meniscal tear is present when abnormal intrameniscal MRI signal disrupts the articular surface (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65888 \" href=\"UTD.htm?14/4/14415\">",
"       image 6",
"      </a>",
"      ). MR arthrography is indicated in the postsurgical evaluation of meniscal retear following prior partial meniscectomy or meniscal repair.",
"      <br/>",
"      <br/>",
"      Discoid meniscus is a congenital malformation manifested by abnormal shape and size, having discoid rather than &ldquo;C&rdquo; shaped appearance. It most commonly affects the lateral meniscus and is associated with increased incidence of meniscal degeneration and tear. MRI is useful to detect the abnormal appearance and complications.",
"     </li>",
"     <li>",
"      CT arthrography &mdash; CT arthrography is a reasonable choice for evaluation of suspected meniscal tear if MRI is contraindicated. Compared with arthroscopy, CT arthrography has a sensitivity and specificity for detecting meniscal tears associated with anterior cruciate ligament (ACL) tears of 92 and 88 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/23\">",
"       23",
"      </a>",
"      ]. Sensitivity and specificity for detecting meniscal tears with intact ACL are 95 and 95 percent, respectively. Sensitivity and specificity for detection of unstable meniscal tears are 97 and 90 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tendon and ligament tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although avulsion fractures that are apparent on plain radiographs may suggest some tendon and ligament tears, MRI is the most useful imaging study to obtain when partial or complete tears are suspected. Injury to the anterior or posterior cruciate ligaments, to the medial collateral ligament, or to lateral stabilizer structures may cause joint laxity.",
"   </p>",
"   <p>",
"    Disruption of the extensor mechanism, including the quadriceps tendon, patellar tendon, and patellar retinaculum, impair knee extension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increase the risk of recurrent patellar dislocation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Tendon and ligament tears can be suspected on plain radiography when avulsion bone injuries are seen, particularly in young athletes. An example of such a fracture is the Segond fracture (avulsion fracture of the lateral tibial condyle).",
"      <br/>",
"      <br/>",
"      Calcification in the medial aspect of the joint, due to a prior or chronic medial collateral ligament tear, is known as the Pellegrini-Stieda lesion.",
"      <br/>",
"      <br/>",
"      Tear of the quadriceps tendon is manifested by low position of the patella (&ldquo;patella baja&rdquo;) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55310 \" href=\"UTD.htm?18/42/19119\">",
"       image 7",
"      </a>",
"      ), and tear of the patellar tendon is seen as superior displacement of the patella (&ldquo;patella alta&rdquo;) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58975 \" href=\"UTD.htm?36/8/37007\">",
"       image 8",
"      </a>",
"      ). Patella alta that is not due to patellar tendon tear may also be seen as a developmental anomaly.",
"     </li>",
"     <li>",
"      MRI and MR arthrography &mdash; MRI evaluates the ligaments and tendons about the knee, including the anterior and posterior cruciate ligaments, the medial collateral ligament, the lateral stabilizer structures, and the extensor mechanism (quadriceps tendon, patellar tendon, and patellar retinaculum). MRI accurately characterizes the degree of injury to the ligaments, which can range from sprain to partial or complete tears.",
"      <br/>",
"      <br/>",
"      MRI of normal tendons demonstrates low signal (dark appearance) on all MRI sequences (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51776 \" href=\"UTD.htm?17/37/18000\">",
"       image 9",
"      </a>",
"      ). One exception in the knee is the quadriceps tendon, which normally exhibits a striated appearance of low and intermediate signal intensity.",
"      <br/>",
"      <br/>",
"      On MRI, a partial tear demonstrates disruption of some fibers of the tendon (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78685 \" href=\"UTD.htm?20/54/21345\">",
"       image 10",
"      </a>",
"      ), and a complete tear shows discontinuity of the entire tendon (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80398 \" href=\"UTD.htm?3/9/3216\">",
"       image 11",
"      </a>",
"      ). MRI demonstrates the quality of the remnants of the tendon in complete tears, the degree of separation of tendon fragments, and the resultant muscle atrophy, which may affect management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anterior cruciate ligament &mdash; As confirmed by findings at arthroscopy or surgery, the sensitivity and specificity of MRI for detecting anterior cruciate ligament (ACL) tears range from 96 to 100 percent and from 98 to 100 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. MRI distinguishes between partial thickness ACL tears, which are usually treated conservatively, and full thickness tears, for which surgical intervention is often recommended. MRI detects otherwise occult osseous and cartilage injuries, which are highly associated with ACL tears and which occur most commonly in the posterolateral tibial plateau and in the lateral femoral condyle [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=see_link\">",
"       \"Anterior cruciate ligament injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Posterior cruciate ligament &mdash; Posterior cruciate ligament (PCL) tears are less common than ACL tears. Isolated PCL injuries are uncommon. PCL injuries are commonly associated with ACL, meniscal, collateral ligament, or posterolateral corner injuries. Most PCL tears are partial thickness, which are usually treated conservatively. PCL injuries associated with bony avulsion, significant knee symptoms with significant PCL laxity, or combined multiple ligamentous injuries are treated surgically [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medial collateral ligament &mdash; The medial (tibial) collateral ligament (MCL) tear is a commonly encountered injury of the knee. This tear is almost always associated with a tear of the joint capsule. Injuries associated with MCL tears include anterior cruciate ligament (ACL) tear and medial meniscus tear, which together are called the &ldquo;unhappy triad.&rdquo; MRI can also detect meniscocapsular separation, which requires immobilization or surgical repair. MCL tear is seldom repaired unless multiple other ligaments are torn. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3257?source=see_link\">",
"       \"Medial collateral ligament injury of the knee\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lateral stabilizing structures &mdash; Injuries to the lateral knee structures are less common than medial knee injuries but may be more disabling, resulting in chronic instability, pain, and secondary osteoarthritis. Most of these injuries are associated with damage to the cruciate ligaments and to the medial knee structures. Posterolateral corner injury is considered a surgical emergency.",
"      <br/>",
"      <br/>",
"      The lateral stabilizing structures have anterolateral and posterolateral components. Anterolateral stabilization is provided by the knee capsule and by the iliotibial tract. Posterolateral stabilization is provided by the arcuate ligament complex, which is comprised of the true lateral collateral ligament; of the biceps femoris tendon; of the popliteus muscle and tendon; of the popliteal meniscal and popliteal fibular ligaments; of the oblique popliteal, arcuate, and fabellofibular ligaments; and of the lateral gastrocnemius muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/30\">",
"       30",
"      </a>",
"      ]. The structures that are assessed routinely by MRI are true lateral collateral ligament, biceps femoris tendon, popliteus muscle and tendon, and lateral gastrocnemius muscle.",
"      <br/>",
"      <br/>",
"      The iliotibial band syndrome is caused by the iliotibial band rubbing on the lateral femoral condyle. It causes anterolateral knee pain and is seen in runners or in those who participate in activities associated with repetitive flexion and extension of the knee. While this condition is readily diagnosed clinically, MRI assessment typically demonstrates fluid along the iliotibial band [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Extensor mechanism injuries &mdash; The extensor mechanism includes the quadriceps tendon, the patellar tendon, and the patellar retinaculum.",
"      <br/>",
"      <br/>",
"      Quadriceps tendon &mdash; The quadriceps tendon may rupture in older adults because of preexisting degeneration, even with minimal or no trauma. Quadriceps tendon rupture is infrequent and may be unilateral or bilateral when caused by systemic disease including hyperparathyroidism, chronic renal failure, gout, obesity, diabetes, steroid abuse, and rheumatoid arthritis. MRI is the modality of choice for diagnosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82182 \" href=\"UTD.htm?26/11/26800\">",
"       image 12",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Patellar tendon &mdash; Proximal patellar tendon ruptures (or &ldquo;jumper&rsquo;s knee&rdquo;) typically occur in younger athletes. Jumper&rsquo;s knee can also involve the quadriceps in 25 percent of the cases. MRI is diagnostic, showing thickening and abnormal signal in the proximal patellar tendon. Jumper&rsquo;s knee can be debilitating and usually requires surgery.",
"      <br/>",
"      <br/>",
"      In adolescents with suspected patellar ligament avulsion injuries (Sinding-Larsen-Johansson and Osgood-Schlatter disease), MRI is valuable in differentiating normal ossification centers from acute injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT arthrography &mdash; CT arthrography is useful to identify injuries to the articular cartilage, cruciate ligaments, and menisci when MRI is unavailable or is contraindicated. When compared with arthroscopic findings, the sensitivity and specificity of CT arthrography for detection of ACL tears range from 87 to 100 percent and from 93 to 97 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/23,32\">",
"       23,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultrasound &mdash; Ultrasound is valuable in evaluating the extensor mechanism, including the quadriceps and patellar tendons. US identifies tendinosis, partial or full thickness tears, degree of tendon retraction, interposed hematoma, or fluid collection. US is helpful in diagnosing iliotibial band syndrome showing thickening and surrounding fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Musculotendinous injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute musculotendinous injuries are comprised of muscle contusion or tear, hematoma, myotendinous strain, and tendon avulsion. Muscle injuries usually occur during sports-related activities and commonly involve the myotendinous junction, which is the weakest point of the muscle. The muscles at highest risk for injury around the knee are the rectus femoris, sartorius, semimembranosus, biceps femoris, and gastrocnemius.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography demonstrates soft tissue swelling in muscle tear and hematoma. Muscle detail is not visualized.",
"     </li>",
"     <li>",
"      MRI and MR arthrography &mdash; MRI identifies and grades the extent of these injuries, including partial tear, complete tear, and hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and CT arthrography &mdash; CT is not optimal for evaluation of the soft tissue, tendons, and ligaments; however, muscle tear and hematoma are identified on CT.",
"     </li>",
"     <li>",
"      Ultrasound &mdash; Ultrasound can demonstrate partial or full thickness tears and hematoma. The quadriceps muscle and tendon and the medial head of gastrocnemius muscle are readily evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ACUTE INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection affecting the knee can involve the surrounding soft tissues (cellulitis, fasciitis, pyomyositis, and abscess), the joint or adjacent bursae (septic arthritis and septic bursitis), and the bone (osteomyelitis and Brodie abscess), which can coexist in advanced cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Soft tissue infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis rarely requires imaging for diagnosis. CT is used to differentiate between superficial cellulitis and cellulitis associated with deep infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/34\">",
"     34",
"    </a>",
"    ]. MRI or CT can be useful to exclude the presence of myositis, abscess, sinus tract, and fasciitis. Contrast administration is valuable. MRI is the most sensitive for detecting early osteomyelitis, although specificity may be somewhat limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Infectious fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography can detect the presence of soft tissue gas in necrotizing fasciitis. CT can detect the presence of gas and can delineate the presence of a soft tissue abscess, although gas is not present in all cases of necrotizing fasciitis. Lack of enhancement of the fascia after contrast administration may confirm the presence of necrosis while distinguishing non-necrotizing from necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/34\">",
"     34",
"    </a>",
"    ]. CT also demonstrates the extent of infection. MRI is highly sensitive for the evaluation of fascial inflammation, evaluating the extent of infection and the presence of abscess or osteomyelitis. However, it is not specific for necrotizing fasciitis, since it does not easily detect small amounts of fascial air.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abscesses can be easily detected with CT or MRI, particularly with the use of intravenous contrast, which better delineates the thickened wall of the abscess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pyomyositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyomyositis can be detected with CT or MRI. Lack of contrast enhancement with CT differentiates between necrotic and viable muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/34\">",
"     34",
"    </a>",
"    ]. MRI is highly sensitive for detection of muscle edema and disease progression to abscess, septic arthritis, or osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Joint infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic arthritis typically presents as an acute, monoarticular arthritis. Joint aspiration is the procedure of choice for diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Radiographs may show soft tissue swelling, effusion, and periarticular osteopenia. In advanced stages, joint destruction with erosive changes is seen (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62141 \" href=\"UTD.htm?31/7/31870\">",
"       image 13",
"      </a>",
"      ). In more indolent infections such as tuberculosis or fungal disease, the joint space may be relatively preserved, and marginal erosions may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12489/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI &mdash; MRI is highly sensitive for detecting joint effusion with septations and debris, synovial thickening, and bone marrow edema (which are nonspecific findings), followed by destruction of the articular cartilage and subjacent bone. Subchondral edema is due to hyperemia; however, further extension of bone marrow edema into the medullary cavity and the degree of change in bone marrow signal intensity are helpful to detect progression to osteomyelitis.",
"     </li>",
"     <li>",
"      CT &mdash; CT is indicated when MRI is not available or is contraindicated for detecting the presence and extent of associated osteomyelitis. CT appearance of septic arthritis includes joint effusion and bone erosions.",
"     </li>",
"     <li>",
"      Radionuclide bone scan &mdash; Bone scan using Tc-99m MDP with three or four phase technique is used in differentiating a septic joint from periarticular infection. Delayed images can detect associated osteomyelitis.",
"     </li>",
"     <li>",
"      Ultrasound &mdash; As noted above, joint aspiration is the procedure of choice for diagnosis of septic arthritis. Joint aspiration can be performed under US if the amount of fluid is small or if the procedure is unsuccessful without imaging guidance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Septic bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic bursitis as a cause of knee symptoms most frequently involves the prepatellar bursa. Ultrasound demonstrates a fluid collection in the expected location of the bursa. US does not allow reliable differentiation between infected and noninfected bursal fluid collections. Diagnostic fluid aspiration should be performed when infection is suspected. MRI also readily demonstrates the presence of bursal fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33256?source=see_link\">",
"     \"Septic bursitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging techniques are an important component in the overall approach to the patient with clinically suspected osteomyelitis. An integrated diagnostic approach and the role of imaging studies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of osteomyelitis in adults\", section on 'Suggested diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following points regarding the limitations of imaging techniques are worth noting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiographs may not reveal any abnormality in the first few weeks of bone infection. Early diagnosis is enhanced by use of more sensitive imaging, particularly MRI with intravenous contrast administration. Radionuclide bone scanning is an alternative when MRI is unavailable or is contraindicated. Findings that may be associated with acute osteomyelitis include soft tissue swelling, joint effusion, periarticular osteopenia, and periosteal reaction. In the proper clinical setting, bone erosion may be virtually diagnostic of osteomyelitis.",
"     </li>",
"     <li>",
"      MRI &mdash; MRI is both sensitive and specific and is the preferred study for suspected early osteomyelitis. MRI can distinguish between periarticular soft tissue infection and osteomyelitis. Intravenous contrast administration better defines the extent of infection, localizes fluid collections, and differentiates between necrotic and viable tissue. However, it is not routinely used, so clinical concern regarding early osteomyelitis should prompt a request for intravenous contrast (unless contraindicated).",
"     </li>",
"     <li>",
"      CT &mdash; CT is valuable for diagnosis when MRI is not available or is contraindicated. CT demonstrates the extent of soft tissue inflammation, periosteal reaction, and cortical and trabecular bony abnormalities.",
"     </li>",
"     <li>",
"      Radionuclide bone scan &mdash; Radionuclide bone scan is highly sensitive but nonspecific in the presence of preexisting bone pathology, joint prostheses, recent surgery, or trauma. If radiographs are normal, three phase bone scan has a sensitivity and specificity of about 95 percent. Imaging with In-111 labeled leukocytes is advocated for detection of osteomyelitis in patients with underlying bone pathology or prosthesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Brodie abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brodie abscess is a subacute localized form of osteomyelitis most commonly caused by Staphylococcus aureus and occurring most commonly in men in the second decade of life. Common locations for Brodie abscess are in the metaphyses of either the femur or the tibia. Plain film radiography and CT demonstrate an elongated, well-defined radiolucent lesion, surrounded by reactive sclerosis. The lesion may extend to and cross the growth plate. MRI is most sensitive for early detection of Brodie abscess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CRYSTAL-ASSOCIATED INFLAMMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute presentations of crystal disease (eg, gout, pseudogout, basic calcium phosphate deposition, etc) can cause acute knee pain with joint, bursal, or tendon sheath inflammation that can mimic infectious processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Calcium pyrophosphate deposition disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium pyrophosphate deposition disease is the most common crystal arthropathy, caused by deposition of calcium pyrophosphate dihydrate (CPPD) crystals in and around the joints. CPPD crystal disease is the second most common arthropathy of the knee, seen predominantly in the middle and older age groups. CPPD crystal deposition is often asymptomatic and is diagnosed on plain film by articular cartilage or meniscal calcification (chondrocalcinosis). When symptomatic, CPPD deposition disease is also called pseudogout. Joint aspiration may be necessary to obtain synovial fluid to confirm the presence of CPPD crystals and to exclude infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography is the gold standard in the radiologic diagnosis of CPPD. Thin calcification is present in the articular cartilage or menisci (chondrocalcinosis), with preferential involvement of the patellofemoral joint. Calcifications of the synovium, tendon, and ligaments can also be seen. CPPD leads to early development of secondary osteoarthritis. Isolated patellofemoral involvement in the knee is always suggestive of CPPD arthropathy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66550 \" href=\"UTD.htm?35/3/35902\">",
"       image 14",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Joint aspiration (arthrocentesis) &mdash; Knee joint aspiration is valuable in the detection of CPPD crystals and serves to exclude joint infection when the clinical manifestation of acute arthritis is present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"       \"Joint aspiration or injection in adults: Technique and indications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee is the third most often affected joint, after the foot and the ankle, among patients with gout. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiographic changes appear in approximately 45 percent of the patients, six to eight years after the initial attack. Collections of urate crystals (tophi) cause erosion of the adjacent bone with typical sclerotic border.",
"     </li>",
"     <li>",
"      Joint aspiration (arthrocentesis) &mdash; Knee joint aspiration is valuable in the detection of monosodium urate crystals and serves to exclude joint infection when the clinical manifestation of gout is present and when the plain film is normal or only demonstrates an effusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"       \"Joint aspiration or injection in adults: Technique and indications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The knee is one of the largest and most complex joints. Radiologic examination is an important part of the process of assessing patients with acute knee pain due to trauma, suspected infection, or crystal induced inflammation.",
"     </li>",
"     <li>",
"      Plain film radiography is usually the first imaging study for an adult with acute knee pain. The standard initial examination includes an anteroposterior (AP) and either a standing or cross table lateral view of the knee. A tunnel projection is indicated if there is concern about fracture of the posterior aspect of the distal femur, and a sunrise projection of the patella and patellofemoral articulation is indicated if a patellar injury is suspected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Bone injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography (CT) is used selectively to assess for fractures that are clinically suspected but are not apparent on plain radiographs and to further assess and aid in preoperative planning for complex fractures.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) is used to assess for soft tissue injuries that cannot be detected by plain film radiography or serves as an alternative to CT for detection of radiographically occult fractures when there is a need to avoid exposure to ionizing radiation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Soft tissue injuries'",
"      </a>",
"      above.) Horizontal or oblique meniscal tears are relatively common in asymptomatic individuals, while radial, vertical, complex, or displaced meniscal tears are strongly associated with knee pain.",
"     </li>",
"     <li>",
"      CT or MR arthrography is used to assess for suspected chondral injuries (chondral fracture or osteochondral fracture). CT arthrography also has a role in assessing for soft tissue injuries (eg, meniscal tear) in patients who have contraindications to MRI. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Meniscal injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Tendon and ligament tears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain film radiographs may detect gas in the soft tissues due to infection and may also detect most clinically significant knee joint effusions. However, joint aspiration is the procedure of choice for diagnosing septic arthritis, gout, and pseudogout, since radiographic findings in these disorders are nonspecific. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Soft tissue infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Joint infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of imaging techniques to assist in the diagnosis of osteomyelitis is summarized briefly above (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Osteomyelitis'",
"      </a>",
"      above) and is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"       \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"      </a>",
"      .) Although plain film radiographs are the first examination for patients with suspected osteomyelitis, they are insensitive for early disease. If plain films are nondiagnostic, further imaging with MRI, CT, or radionuclide scanning may be informative.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/1\">",
"      Frick MA, Wenger DE, Adkins M. MR imaging of synovial disorders of the knee: an update. Radiol Clin North Am 2007; 45:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/2\">",
"      Fox MG. MR imaging of the meniscus: review, current trends, and clinical implications. Radiol Clin North Am 2007; 45:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/3\">",
"      Mustonen AO, Koskinen SK, Kiuru MJ. Acute knee trauma: analysis of multidetector computed tomography findings and comparison with conventional radiography. Acta Radiol 2005; 46:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/4\">",
"      Macarini L, Murrone M, Marini S, et al. Tibial plateau fractures: evaluation with multidetector-CT. Radiol Med 2004; 108:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/5\">",
"      Wicky S, Blaser PF, Blanc CH, et al. Comparison between standard radiography and spiral CT with 3D reconstruction in the evaluation, classification and management of tibial plateau fractures. Eur Radiol 2000; 10:1227.",
"     </a>",
"    </li>",
"    <li>",
"     Greenspan A. Lower limb II: Knee. In: Orthopedic Imaging: A Practical Approach, 4th, Greenspan A (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/7\">",
"      Deutsch AL, Mink JH, Shellock FG. Magnetic resonance imaging of injuries to bone and articular cartilage. Emphasis on radiographically occult abnormalities. Orthop Rev 1990; 19:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/8\">",
"      Kode L, Lieberman JM, Motta AO, et al. Evaluation of tibial plateau fractures: efficacy of MR imaging compared with CT. AJR Am J Roentgenol 1994; 163:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/9\">",
"      Elias DA, White LM. Imaging of patellofemoral disorders. Clin Radiol 2004; 59:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/10\">",
"      Oeppen RS, Connolly SA, Bencardino JT, Jaramillo D. Acute injury of the articular cartilage and subchondral bone: a common but unrecognized lesion in the immature knee. AJR Am J Roentgenol 2004; 182:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/11\">",
"      Bredella MA, Tirman PF, Peterfy CG, et al. Accuracy of T2-weighted fast spin-echo MR imaging with fat saturation in detecting cartilage defects in the knee: comparison with arthroscopy in 130 patients. AJR Am J Roentgenol 1999; 172:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/12\">",
"      Rubin DA, Harner CD, Costello JM. Treatable chondral injuries in the knee: frequency of associated focal subchondral edema. AJR Am J Roentgenol 2000; 174:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/13\">",
"      Ramappa AJ, Gill TJ, Bradford CH, et al. Magnetic resonance imaging to assess knee cartilage repair tissue after microfracture of chondral defects. J Knee Surg 2007; 20:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/14\">",
"      Tuite MJ, Daffner RH, Weissman BN, et al. ACR appropriateness criteria(&reg;) acute trauma to the knee. J Am Coll Radiol 2012; 9:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/15\">",
"      Maskell TW, Finlay DB. The prognostic significance of radiologically detected knee joint effusions in the absence of associated fracture. Br J Radiol 1990; 63:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/16\">",
"      Duncan JB, Hunter R, Purnell M, Freeman J. Injured stable knee with acute effusion: MRI evaluation. J South Orthop Assoc 1996; 5:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/17\">",
"      Lee MJ, Chow K. Ultrasound of the knee. Semin Musculoskelet Radiol 2007; 11:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/18\">",
"      Sch&auml;fer FK, Sch&auml;fer PJ, Brossmann J, et al. Value of fat-suppressed proton-density-weighted turbo spin-echo sequences in detecting meniscal lesions: comparison with arthroscopy. Acta Radiol 2006; 47:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/19\">",
"      Oei EH, Nikken JJ, Verstijnen AC, et al. MR imaging of the menisci and cruciate ligaments: a systematic review. Radiology 2003; 226:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/20\">",
"      Magee T, Williams D. 3.0-T MRI of meniscal tears. AJR Am J Roentgenol 2006; 187:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/21\">",
"      Boden SD, Davis DO, Dina TS, et al. A prospective and blinded investigation of magnetic resonance imaging of the knee. Abnormal findings in asymptomatic subjects. Clin Orthop Relat Res 1992; :177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/22\">",
"      Zanetti M, Pfirrmann CW, Schmid MR, et al. Patients with suspected meniscal tears: prevalence of abnormalities seen on MRI of 100 symptomatic and 100 contralateral asymptomatic knees. AJR Am J Roentgenol 2003; 181:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/23\">",
"      Vande Berg BC, Lecouvet FE, Poilvache P, et al. Anterior cruciate ligament tears and associated meniscal lesions: assessment at dual-detector spiral CT arthrography. Radiology 2002; 223:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/24\">",
"      Vande Berg BC, Lecouvet FE, Poilvache P, et al. Dual-detector spiral CT arthrography of the knee: accuracy for detection of meniscal abnormalities and unstable meniscal tears. Radiology 2000; 216:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/25\">",
"      Ha TP, Li KC, Beaulieu CF, et al. Anterior cruciate ligament injury: fast spin-echo MR imaging with arthroscopic correlation in 217 examinations. AJR Am J Roentgenol 1998; 170:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/26\">",
"      Cotten A, Delfaut E, Demondion X, et al. MR imaging of the knee at 0.2 and 1.5 T: correlation with surgery. AJR Am J Roentgenol 2000; 174:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/27\">",
"      Nawata K, Teshima R, Suzuki T. Osseous lesions associated with anterior cruciate ligament injuries. Assessment by magnetic resonance imaging at various periods after injuries. Arch Orthop Trauma Surg 1993; 113:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/28\">",
"      Kaplan PA, Walker CW, Kilcoyne RF, et al. Occult fracture patterns of the knee associated with anterior cruciate ligament tears: assessment with MR imaging. Radiology 1992; 183:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/29\">",
"      Sanders TG. MR imaging of postoperative ligaments of the knee. Semin Musculoskelet Radiol 2002; 6:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/30\">",
"      Recondo JA, Salvador E, Villan&uacute;a JA, et al. Lateral stabilizing structures of the knee: functional anatomy and injuries assessed with MR imaging. Radiographics 2000; 20 Spec No:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/31\">",
"      Muhle C, Ahn JM, Yeh L, et al. Iliotibial band friction syndrome: MR imaging findings in 16 patients and MR arthrographic study of six cadaveric knees. Radiology 1999; 212:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/32\">",
"      Lee W, Kim HS, Kim SJ, et al. CT arthrography and virtual arthroscopy in the diagnosis of the anterior cruciate ligament and meniscal abnormalities of the knee joint. Korean J Radiol 2004; 5:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/33\">",
"      Berquist TH. Osseous and myotendinous injuries about the knee. Radiol Clin North Am 2007; 45:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12489/abstract/34\">",
"      Fayad LM, Carrino JA, Fishman EK. Musculoskeletal infection: role of CT in the emergency department. Radiographics 2007; 27:1723.",
"     </a>",
"    </li>",
"    <li>",
"     Brower AC. Approach to the knee. In: Arthritis in Black and White, 2nd, Brower AC, Flemming DJ (Eds), WB Saunders Company, Philadelphia 1997.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1833 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12489=[""].join("\n");
var outline_f12_12_12489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bone injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute chondral and osteochondral injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Soft tissue injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Knee joint effusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Meniscal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tendon and ligament tears",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Musculotendinous injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACUTE INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cellulitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Infectious fasciitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Joint infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Septic bursitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Brodie abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CRYSTAL-ASSOCIATED INFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Calcium pyrophosphate deposition disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1833|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/35/12863\" title=\"diagnostic image 1\">",
"      Comminuted patella fract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/21/42334\" title=\"diagnostic image 2\">",
"      Lat tibial avulsion fract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/61/33759\" title=\"diagnostic image 3\">",
"      Tibial spine fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/2/28718\" title=\"diagnostic image 4\">",
"      Knee fat fluid level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/49/36638\" title=\"diagnostic image 5\">",
"      Traumatic knee effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/4/14415\" title=\"diagnostic image 6\">",
"      Oblique med meniscus tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/42/19119\" title=\"diagnostic image 7\">",
"      Chronic quad tendon tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/8/37007\" title=\"diagnostic image 8\">",
"      Patellar tendon tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/37/18000\" title=\"diagnostic image 9\">",
"      Norm ad sagital knee MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/54/21345\" title=\"diagnostic image 10\">",
"      Part patella tendon tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/9/3216\" title=\"diagnostic image 11\">",
"      ACL full thickness tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/11/26800\" title=\"diagnostic image 12\">",
"      Full thick quad tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/7/31870\" title=\"diagnostic image 13\">",
"      Septic knee radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/3/35902\" title=\"diagnostic image 14\">",
"      Chondrocalcin knee x ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1833|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/27/35251\" title=\"figure 1\">",
"      Anterior anatomy of knee",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=related_link\">",
"      Anterior cruciate ligament injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=related_link\">",
"      Approach to the young athlete with chronic knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=related_link\">",
"      Diagnostic imaging of joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3257?source=related_link\">",
"      Medial collateral ligament injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33256?source=related_link\">",
"      Septic bursitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_12_12490="Constrictive pericarditis";
var content_f12_12_12490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Constrictive pericarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12490/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12490/contributors\">",
"     Brian D Hoit, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12490/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12490/contributors\">",
"     Martin M LeWinter, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12490/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12490/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/12/12490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/12/12490/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/12/12490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pericardium is a fibroelastic sac surrounding the heart that contains a thin layer of fluid. When larger amounts of fluid accumulate (pericardial effusion) or when the pericardium becomes scarred and inelastic, one of three pericardial compressive syndromes may occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac tamponade &ndash; Cardiac tamponade, which may be acute or subacute, is characterized by the accumulation of pericardial fluid under pressure. Variants include low pressure (occult) and regional tamponade.",
"     </li>",
"     <li>",
"      Constrictive pericarditis &ndash; Constrictive pericarditis is the result of scarring and consequent loss of the normal elasticity of the pericardial sac. Pericardial constriction is typically chronic, but variants include subacute, transient, and occult constriction.",
"     </li>",
"     <li>",
"      Effusive-constrictive pericarditis &ndash; Effusive-constrictive pericarditis is characterized by underlying constrictive physiology with a coexisting pericardial effusion, often with cardiac tamponade [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/1\">",
"       1",
"      </a>",
"      ]. This usually results in a mixed hemodynamic picture with features of both constriction and tamponade. Such patients may be mistakenly thought to have only cardiac tamponade; however, elevation of the right atrial and pulmonary wedge pressures after drainage of the pericardial fluid points to the underlying constrictive process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both typical constrictive pericarditis and effusive-constrictive pericarditis, cardiac filling is impeded by an external force. The normal pericardium can stretch to accommodate physiologic changes in cardiac volume. However, after its reserve volume is exceeded the pericardium markedly stiffens. In severe pericardial compressive syndromes, the pericardium becomes virtually inelastic, resulting in minimal ability to adapt to volume changes.",
"   </p>",
"   <p>",
"    As a result, an important pathophysiologic feature of constrictive pericarditis is greatly enhanced ventricular interdependence, in which the hemodynamics of the left and right heart chambers are directly influenced by each other to a much greater degree than normal. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hemodynamic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The physiology, clinical presentation, diagnosis, and treatment of constrictive pericarditis and effusive-constrictive pericarditis will be reviewed here. Issues related to cardiac tamponade, and the evaluation and management of pericardial diseases that do not compromise hemodynamics, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188581749\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a normal pericardium, intrathoracic pressure decreases during inspiration, leading to an increase in venous return to the right heart and transient increase in right ventricular chamber size. Because the normal pericardium accommodates the increased venous return by expanding, this increase in venous return does not impair left ventricular filling.",
"   </p>",
"   <p>",
"    In constrictive pericarditis the upper limit of cardiac volume is constrained by the inelastic pericardium. The thickened, rigid pericardium prevents the normal inspiratory decrease in intrathoracic pressure from being transmitted to the heart chambers. The abnormal pericardium also does not expand to accommodate increased venous return to the right heart during inspiration. Thus, pulmonary venous pressure, but not left ventricular pressure, declines during inspiration, leading to a reduction in left ventricular volume because of a decrease in the transpulmonary gradient. Because of ventricular interaction, the right heart volume expands via shifting of the interventricular septum. This interaction between the left and right ventricles is termed ventricular interdependence.",
"   </p>",
"   <p>",
"    With constrictive pericarditis, early diastolic filling is even more rapid than normal. Compression does not occur until the cardiac volume approximates that of the pericardium, which begins in mid-diastole. As a result, virtually all ventricular filling occurs in early diastole with little or no filling subsequently. As constrictive pericarditis becomes more severe, ventricular volumes and stroke volumes are reduced.",
"   </p>",
"   <p>",
"    The hemodynamic findings and distinction between constrictive pericarditis and restrictive cardiomyopathy are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constrictive pericarditis can occur after virtually any pericardial disease process, but only rarely follows recurrent acute pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/2\">",
"     2",
"    </a>",
"    ]. The following causes of constrictive pericarditis were identified in case series from tertiary care centers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link\">",
"     \"Recurrent pericarditis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic or viral &ndash; 42 to 49 percent",
"     </li>",
"     <li>",
"      Post-cardiac surgery &ndash; 11 to 37 percent",
"     </li>",
"     <li>",
"      Post-radiation therapy &ndash; 9 to 31 percent, primarily after Hodgkin disease or breast cancer",
"     </li>",
"     <li>",
"      Connective tissue disorder &ndash; 3 to 7 percent",
"     </li>",
"     <li>",
"      Postinfectious (tuberculous or purulent pericarditis) &ndash; 3 to 6 percent",
"     </li>",
"     <li>",
"      Miscellaneous causes (malignancy, trauma, drug-induced, asbestosis, sarcoidosis, uremic pericarditis) &ndash; 1 to 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of constrictive pericarditis following a first episode of acute pericarditis was assessed in 500 patients prospectively studied over a mean follow-up of six years (24 to 120 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/6\">",
"     6",
"    </a>",
"    ]. Constrictive pericarditis developed in 1.8 percent (2 of 416 patients with",
"    <span class=\"nowrap\">",
"     idiopathic/viral",
"    </span>",
"    pericarditis and 7 of 84 patients with a",
"    <span class=\"nowrap\">",
"     nonviral/nonidiopathic",
"    </span>",
"    etiology). The incidence rate of constrictive pericarditis was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Idiopathic/viral",
"      </span>",
"      &ndash; 0.76 cases per 1000 person-years",
"     </li>",
"     <li>",
"      Connective",
"      <span class=\"nowrap\">",
"       tissue/pericardial",
"      </span>",
"      injury syndrome &ndash; 4.40 cases per 1000 person-years",
"     </li>",
"     <li>",
"      Neoplastic pericarditis &ndash; 6.33 cases per 1000 person-years",
"     </li>",
"     <li>",
"      Tuberculous pericarditis &ndash; 31.65 cases per 1000 person-years",
"     </li>",
"     <li>",
"      Purulent pericarditis &ndash; 52.75 cases per 1000 person-years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cases of constrictive pericarditis following orthotopic heart transplant have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/7\">",
"     7",
"    </a>",
"    ]. Tuberculosis accounted for 49 percent of cases of constrictive pericarditis in a series reported in 1962 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/8\">",
"     8",
"    </a>",
"    ]. While tuberculosis is now only a rare cause of constrictive pericarditis in developed countries, it should be considered as a possible etiology among patients at high risk of developing active tuberculosis, including those from endemic areas and patients with HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"     \"Tuberculous pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15913768\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with constrictive pericarditis typically present with one or both of the following constellations of symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms related to fluid overload, ranging from peripheral edema to anasarca",
"     </li>",
"     <li>",
"      Symptoms related to diminished cardiac output in response to exertion, such as fatigability and dyspnea on exertion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one series of 135 patients, 67 percent of patients presented with symptoms of heart failure, 8 percent with chest pain, 6 percent with abdominal symptoms, 4 percent with atrial arrhythmia, and only 5 percent with symptoms of cardiac tamponade (eg, dyspnea, fatigue, reduced exercise capacity) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with constrictive pericarditis display elevated jugular venous pressure (JVP) on physical examination. Other important but less common features on the physical examination include pulsus paradoxus, Kussmaul&rsquo;s sign, a pericardial knock, edema, ascites,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cachexia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated JVP has been reported in as many as 93 percent of patients with surgically confirmed constrictive pericarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/4\">",
"       4",
"      </a>",
"      ]. The characteristics of the jugular venous waveforms in patients with constrictive pericarditis are different from those in normal patients and patients with other types of cardiac disease (",
"      <a class=\"graphic graphic_figure graphicRef80995 \" href=\"UTD.htm?40/1/40976\">",
"       figure 1",
"      </a>",
"      ). The x and y troughs are more prominent than the a and v peaks and the inspiratory decline in venous pressure is confined to the depth of the y descent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hemodynamic evaluation'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Pericardial constriction should be considered in any patient with an unexplained elevation in JVP, particularly if there is a history of a predisposing condition such as malignancy, prior cardiac surgery, or prior radiation therapy.",
"      <br/>",
"      <br/>",
"      JVP may be normal in patients with early or mild constrictive pericarditis. In addition, occult constrictive pericarditis has been described in patients who are volume depleted; in this setting, the increase in venous pressure may not be apparent prior to volume expansion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Occult constrictive pericarditis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Pulsus paradoxus (an exaggerated drop in systemic blood pressure greater than 10 mmHg during inspiration) occurs in less than 20 percent of patients with constrictive pericarditis (",
"      <a class=\"graphic graphic_waveform graphicRef70731 \" href=\"UTD.htm?31/27/32180\">",
"       waveform 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/4,10\">",
"       4,10",
"      </a>",
"      ]. It may be more common in patients with concomitant pericardial effusion with cardiac tamponade or coexisting pulmonary disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=see_link\">",
"       \"Pulsus paradoxus in pericardial disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Kussmaul's sign (the lack of an inspiratory decline in JVP) is present in patients with constrictive pericarditis, but does not distinguish constrictive pericarditis from severe tricuspid valve disease or right-sided heart failure. While case series have noted rates of 13 to 21 percent, Kussmaul's sign is more common in our experience [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A pericardial knock, an accentuated heart sound occurring slightly earlier than an S3 which may be audible and rarely is palpable, has been reported in 47 percent of patients with constrictive pericarditis in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/4\">",
"       4",
"      </a>",
"      ]. Sixteen percent of patients in the same series had a pericardial friction rub.",
"     </li>",
"     <li>",
"      Profound cachexia, peripheral edema, ascites, pulsatile hepatomegaly (part of the syndrome of congestive hepatopathy), and pleural effusion are common findings with more severe constrictive pericarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274012956\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected constrictive pericarditis, based on history and physical examination, should undergo initial evaluation with electrocardiography, chest radiography, and echocardiography. While the diagnosis of constrictive pericarditis is often made by echocardiography, patients commonly undergo cardiac catheterization prior to surgical intervention. Invasive hemodynamic evaluation during cardiac catheterization can confirm the diagnosis and concurrent coronary angiography defines the patient&rsquo;s coronary anatomy prior to possible surgical intervention. In patients being evaluated for pericardiectomy, particularly those with prior radiation exposure, computed tomography or cardiac magnetic resonance imaging can provide additional detailed anatomic information about adjacent vascular structures and the extent of pericardial thickening, calcification, and scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no pathognomonic electrocardiographic findings in constrictive pericarditis. Nonspecific ST and T wave changes and tachycardia are common, and low voltage may sometimes be present. In advanced cases, atrial fibrillation is common due to increased atrial pressures. In a series of 143 patients with surgically confirmed constrictive pericarditis, 22 percent had atrial fibrillation and 27 percent had low voltage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of pericardial calcification by chest radiograph, especially in conjunction with the appropriate clinical presentation, is highly consistent with constrictive pericarditis. However, the majority of patients with constrictive pericarditis will",
"    <strong>",
"     not",
"    </strong>",
"    have pericardial calcification, so its absence does not exclude constrictive pericarditis.",
"   </p>",
"   <p>",
"    Chest radiographs that demonstrate a ring of calcification around the heart, best seen on lateral or anterior oblique projections, strongly suggest constrictive pericarditis in patients with symptoms of right-sided heart failure (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64005 \" href=\"UTD.htm?12/18/12578\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/11\">",
"     11",
"    </a>",
"    ]. Pericardial calcification can occur in the absence of constriction, but is usually less dense and has a patchy distribution. A retrospective review of 135 patients with constrictive pericarditis confirmed surgically or at autopsy reported that 36 patients (27 percent) had pericardial calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared to those without calcification, patients with calcification had the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A greater likelihood of having idiopathic pericardial disease (67 versus 21 percent)",
"     </li>",
"     <li>",
"      A longer duration of symptoms",
"     </li>",
"     <li>",
"      A greater likelihood of having a pericardial knock, larger atria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atrial arrhythmias",
"     </li>",
"     <li>",
"      A higher perioperative mortality, but the same long-term survival",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transthoracic echocardiography (TTE) is an essential diagnostic test in patients being evaluated for constrictive pericarditis. The American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Society of Echocardiography guidelines recommend the use echocardiography for the evaluation of all patients with suspected pericardial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/14\">",
"     14",
"    </a>",
"    ]. Two-dimensional and M-mode echocardiography allow structural visualization while Doppler echocardiography provides hemodynamic information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15194949\">",
"    <span class=\"h3\">",
"     Two-dimensional and M mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;One or more of the following findings may be seen by two-dimensional or M-mode echocardiography in patients with constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/2,11,12,15,16\">",
"     2,11,12,15,16",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27077?source=see_link\">",
"     \"Echocardiographic evaluation of the pericardium\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased pericardial thickness &ndash; TTE demonstrates increased pericardial thickness with or without calcification in approximately 40 percent of patients. Mildly increased pericardial thickening is often missed, and false positive results suggesting calcification can be obtained if the gain setting is too high. In comparison, measurement of pericardial thickness by transesophageal echocardiography (TEE) correlates strongly with that obtained by computed tomography [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      M mode &ndash; No sign or combination of signs on M-mode is diagnostic of constrictive pericarditis. However, a normal M-mode study with none of the following findings virtually rules out the diagnosis of constrictive pericarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/18\">",
"       18",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abrupt posterior motion of the ventricular septum in early diastole with inspiration (septal shudder and bounce) caused by underfilling of the left ventricle (due to the decreased pulmonary vein-left atrial gradient with inspiration).",
"     </li>",
"     <li>",
"      Systemic venous return is not increased with inspiration due to volume constraints imposed by the abnormal pericardium [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Notching of the ventricular septal tracing in early diastole or with atrial systole due to a transient reversal of ventricular septal transmural pressure at these times in the cardiac cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rapid posterior motion of the left ventricular posterior wall in early diastole followed by a flattening of the wall in mid diastole (also a feature of restrictive cardiomyopathy).",
"     </li>",
"     <li>",
"      Premature opening of the pulmonic valve as right ventricular diastolic pressure rises above pulmonary arterial pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two-dimensional echocardiography &ndash; Two-dimensional echocardiography may reveal [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dilatation of the inferior vena cava and hepatic veins (plethora) with absent or diminished inspiratory collapse.",
"     </li>",
"     <li>",
"      Moderate biatrial enlargement (severe enlargement is more compatible with restrictive cardiomyopathy).",
"     </li>",
"     <li>",
"      A sharp halt in ventricular diastolic filling (corresponding to the end of early rapid diastolic filling as noted on Doppler).",
"     </li>",
"     <li>",
"      Septal bounce with abrupt transient rightward movement of the interventricular septum.",
"     </li>",
"     <li>",
"      Hypermobile atrioventricular valves.",
"     </li>",
"     <li>",
"      An abnormal contour between the posterior left ventricular and left atrial walls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a reported series of 143 patients with surgically confirmed constriction, 138 underwent TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/12\">",
"     12",
"    </a>",
"    ]. Increased pericardial thickness was seen in 37 percent, abnormal septal motion in 49 percent, and atrial enlargement in 61 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15194964\">",
"    <span class=\"h3\">",
"     Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler echocardiography is critical for the diagnosis of constrictive pericarditis. The following findings on Doppler echocardiography are suggestive of constrictive pericarditis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal passive filling of the ventricles during early diastole &mdash; High E velocity of right and left ventricle (LV) inflow is seen due to the abnormally rapid early diastolic filling associated with the combination of a small ventricular volume and rapid recoil. The early diastolic Doppler tissue velocity at the mitral annulus (E') is prominent (unless slowed by mitral annular calcification). The usually positive linear relation between",
"      <span class=\"nowrap\">",
"       E/E&rsquo;",
"      </span>",
"      and left atrial pressure, which is useful for assessing left atrial pressure in cardiomyopathy, is reversed (annular paradox) in constrictive pericarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"       \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Annular early diastolic (E') velocities are lower in constrictive pericarditis secondary to surgery or radiation than idiopathic or post-pericarditis etiologies. The mitral",
"      <span class=\"nowrap\">",
"       lateral/medial",
"      </span>",
"      E' ratio is reversed in the majority of patients with constrictive pericarditis. After pericardiectomy, annular velocities are reduced, and the",
"      <span class=\"nowrap\">",
"       lateral/medial",
"      </span>",
"      E' ratio normalizes [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The propagation velocity of early diastolic transmitral flow on color M-mode is normal or increased.",
"     </li>",
"     <li>",
"      Pronounced respiratory variation in ventricular filling &mdash; Mitral inflow velocity falls as much as 25 to 40 percent and tricuspid velocity greatly increases in the first cardiac cycle following inspiration. The respiratory variation in pulmonary venous flow is even more pronounced [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/25\">",
"       25",
"      </a>",
"      ]. These phenomena, which are manifestations of ventricular interdependence, are not present in either normal subjects or patients with restrictive cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/26\">",
"       26",
"      </a>",
"      ]. Increased respiratory variation of mitral inflow may be missing in patients with markedly elevated left atrial pressure, but can sometimes be elicited in such patients by preload reduction with semi-recumbent (rather than supine) positioning or diuretic administration [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatic venous flow reversal increases with expiration, reflecting the ventricular interdependence and the dissociation of intracardiac and intrathoracic pressures [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomographic (CT) scanning of the heart, obtained by rapid scanning gated to the cardiac cycle, is useful in the diagnosis of constrictive pericarditis and can provide additional data to guide perioperative management decisions.",
"   </p>",
"   <p>",
"    Findings on CT include increased pericardial thickness and calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/11\">",
"     11",
"    </a>",
"    ]. In a review of 143 patients with surgically confirmed constrictive pericarditis, 97 underwent preoperative CT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/12\">",
"     12",
"    </a>",
"    ]. A pathologically thickened pericardium (&gt;4 mm) was seen in 72 percent and pericardial calcification in 25 percent. A normal appearance, or nonvisualization, of the pericardium does not rule out constrictive pericarditis. Other findings on CT scanning which suggest constrictive pericarditis include dilatation of the inferior vena cava, deformed ventricular contours, and angulation of the ventricular septum. Nonvisualization of the posterolateral left ventricular wall on dynamic CT may indicate myocardial fibrosis or atrophy and is associated with a poor surgical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT imaging may also be used to examine the effect of cardiac motion transmitted to the surrounding pulmonary parenchyma. Failure of the immediately adjacent pulmonary structures to pulsate during the cardiac cycle, in the presence of a regionally or globally thickening pericardium, is virtually diagnostic of constrictive pericarditis.",
"   </p>",
"   <p>",
"    CT may assist in the preoperative planning of pericardiectomy in patients with a history of previous cardiothoracic surgery given its ability to identify critical vascular structures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/29\">",
"     29",
"    </a>",
"    ]. Additionally, in selected patients, CT offers the ability to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assess the extent of lung injury in patients with previous radiation exposure",
"     </li>",
"     <li>",
"      Evaluate the location and extent of pericardial calcification",
"     </li>",
"     <li>",
"      Avoid the need for invasive coronary angiography in those with normal CT coronary angiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gated cardiac magnetic resonance imaging (CMR) provides direct visualization of the normal pericardium, which is composed of fibrous tissue and has a low MRI signal intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/30\">",
"     30",
"    </a>",
"    ]. CMR is advocated by some as the diagnostic procedure of choice for the detection of certain pericardial diseases, including constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Characteristic CMR features in patients with constrictive pericarditis include increased pericardial thickening and dilatation of the inferior vena cava, an indirect sign of impaired right ventricular diastolic filling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While computed tomography (CT) is superior to CMR in detecting calcification, CMR better differentiates small effusions from pericardial thickening. CMR also has the potential to resolve hemodynamic events such as septal bounce and to better identify pericardial inflammation and pericardial-myocardial adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/29\">",
"     29",
"    </a>",
"    ]. CMR with Late gadolinium enhancement (LGE) of the pericardium seen during CMR is fairly common but not universal in patients with constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Persons with constrictive pericarditis and pericardial LGE had greater fibroblast proliferation, chronic inflammation, and pericardial thickening compared to those without LGE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/35\">",
"     35",
"    </a>",
"    ]. Pericardial LGE might also be a predictor of reversibility of constrictive pericarditis following treatment with antiinflammatory agents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest using CMR imaging in patients being considered for pericardiectomy to provide additional detailed anatomic information that might alter the decision to proceed with surgery based on the likelihood of resolution with medical therapy alone. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Transient constrictive pericarditis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hemodynamic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive hemodynamic evaluation is occasionally needed to confirm the diagnosis of constrictive pericarditis, particularly in patients with suboptimal or nondiagnostic echocardiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/2\">",
"     2",
"    </a>",
"    ]. Moreover, patients with diagnostic-quality echocardiographic findings may require coronary angiography for evaluation of coronary anatomy prior to pericardiectomy. In this setting, an invasive hemodynamic evaluation may also be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major hemodynamic findings in patients with constrictive pericarditis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased right atrial pressure.",
"     </li>",
"     <li>",
"      Prominent x and y descents of venous and atrial pressure tracings (",
"      <a class=\"graphic graphic_figure graphicRef80995 \" href=\"UTD.htm?40/1/40976\">",
"       figure 1",
"      </a>",
"      ). In contrast, the y descent of diastolic ventricular filling is absent in tamponade. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H13#H13\">",
"       \"Cardiac tamponade\", section on 'Physical findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Kussmaul's sign (the lack of an inspiratory decline or an inspiratory increase in central venous pressure).",
"     </li>",
"     <li>",
"      Increased RV end-diastolic pressure, usually to a level one-third or more of RV systolic pressure.",
"     </li>",
"     <li>",
"      \"Square root\" signs in the RV and LV diastolic pressure tracings (an early diastolic dip followed by a plateau of diastasis; the last stage of diastole just before contraction), often with an absent a wave [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/11\">",
"       11",
"      </a>",
"      ]. This finding, also called dip and plateau, reflects rapid early diastolic filling of the ventricles, followed by lack of additional filling due to compression in mid and late diastole (",
"      <a class=\"graphic graphic_figure graphicRef81335 \" href=\"UTD.htm?6/59/7097\">",
"       figure 2",
"      </a>",
"      ). The plateau configuration (of the dip and plateau pattern) may be diminished or absent in patients who are tachycardic due to the shortening of diastole.",
"     </li>",
"     <li>",
"      A greater inspiratory fall in pulmonary capillary wedge pressure compared to left ventricular diastolic pressure.",
"     </li>",
"     <li>",
"      Equalization of LV and RV diastolic plateau pressure tracings, with little separation with exercise, since filling, and therefore diastolic pressure, in both ventricles is constrained by the inelastic pericardium [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/11\">",
"       11",
"      </a>",
"      ]. In some patients, this finding is seen only during inspiration (",
"      <a class=\"graphic graphic_waveform graphicRef80355 \" href=\"UTD.htm?18/54/19296\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mirror-image discordance between RV and peak LV systolic pressures during inspiration, another sign of increased ventricular interdependence. During peak inspiration, an increase in RV pressure occurs when LV pressure is lowest [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/36\">",
"       36",
"      </a>",
"      ]. These changes can be detected by both invasive hemodynamic monitoring and Doppler echocardiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 143 patients with surgically confirmed constrictive pericarditis, 78 underwent cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/12\">",
"     12",
"    </a>",
"    ]. The mean right atrial pressure was 21 mmHg. A dip and plateau pattern was seen in 77 percent, diastolic equalization of pressures in 81 percent, and respiratory variation in the RV-LV pressure relationship in 44 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12858639\">",
"    <span class=\"h2\">",
"     Plasma BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma concentrations of brain natriuretic peptide (BNP) are increased in patients with left ventricular dysfunction; as a result, plasma BNP is used in the evaluation of dyspnea and to assess the efficacy of therapy and estimate prognosis in patients with heart failure (HF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with cardiomyopathy, BNP is released in response to left ventricular dysfunction and wall stretch. However, wall stretch is limited in constrictive pericarditis by the thickened stiff pericardium. These physiologic differences suggest that the elevation in plasma BNP in constrictive pericarditis should be much less than in other types of cardiomyopathy (eg, restrictive cardiomyopathy), which is consistent with findings of small studies showing BNP values to be lower in patients with constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link&amp;anchor=H740032#H740032\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\", section on 'Plasma BNP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and physical findings in patients with constrictive pericarditis are similar to those of several other disorders. Most importantly, the clinician must distinguish between constrictive pericarditis, which is treated by pericardiectomy; cardiac tamponade, which is treated by drainage of the pericardial effusion; and disorders such as restrictive cardiomyopathy and cirrhosis, which require markedly different treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12858374\">",
"    <span class=\"h2\">",
"     Comparison with restrictive cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with both constrictive pericarditis and restrictive cardiomyopathy have elevated left and right sided filling pressures, often of equal magnitude, and usually have normal systolic ventricular function. While the history, physical examination, and radiographic findings may suggest a particular diagnosis, constrictive pericarditis and restrictive cardiomyopathy are usually distinguished by hemodynamic findings from Doppler echocardiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac catheterization. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history and physical examination may provide helpful clues to the diagnosis. Constrictive pericarditis is suggested in a patient with prior pericarditis or a systemic disease predisposing to constrictive pericarditis (eg, tuberculosis). Restrictive cardiomyopathy is more likely in a patient with a predisposing systemic disease such as diabetes mellitus or amyloidosis. A pericardial knock favors constrictive pericarditis, but is difficult to distinguish from the third heart sound of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link&amp;anchor=H2#H2\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\", section on 'History and physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic findings may also provide clues to the diagnosis. Increased thickness or calcification of the pericardium favors the diagnosis of constrictive pericarditis, while myocardial thickening and abnormal myocardial texture suggest restrictive cardiomyopathy. Although increased pericardial thickness is a highly specific finding for the diagnosis of constrictive pericarditis, it is not present in all patients. In one series of patients with surgically confirmed constrictive pericarditis, pericardial thickening was seen in only 37 percent by transthoracic echocardiogram and 72 percent by computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/12\">",
"     12",
"    </a>",
"    ]. On histopathologic examination of pericardiectomy specimens, 26 patients (18 percent) had normal pericardial thickness.",
"   </p>",
"   <p>",
"    Hemodynamic findings that distinguish the two conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory variation in ventricular inflow velocities &ndash; Doppler echocardiography reveals an abnormal increase in respiratory variation of the ventricular inflow velocities in patients with constrictive pericarditis compared to a normal pattern in patients with restrictive cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H15194964\">",
"       'Doppler'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatic venous flow reversal &ndash; Hepatic venous flow usually reverses during expiration in constrictive pericarditis but reverses during inspiration in restrictive cardiomyopathy.",
"     </li>",
"     <li>",
"      Doppler tissue velocity &ndash; The early diastolic Doppler tissue velocity at the mitral annulus (E') is decreased (&lt;8",
"      <span class=\"nowrap\">",
"       cm/sec)",
"      </span>",
"      in restrictive cardiomyopathy, due to an intrinsic decrease in myocardial contraction and relaxation. In contrast, the transmitral E' is frequently increased (&gt;12",
"      <span class=\"nowrap\">",
"       cm/sec)",
"      </span>",
"      in constrictive pericarditis, since the longitudinal movement of the myocardium is enhanced because of constricted radial motion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/23,37\">",
"       23,37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15194964\">",
"       'Doppler'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      While E' values &lt;8",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      or &gt;12",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      are highly specific for constrictive pericarditis or restrictive cardiomyopathy, many patients will have an E' velocity between 8",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      and 12",
"      <span class=\"nowrap\">",
"       cm/sec,",
"      </span>",
"      which is nondiagnostic. Despite excellent specificity of E' for differentiating restrictive cardiomyopathy from constrictive pericarditis, its sensitivity is more modest.",
"     </li>",
"     <li>",
"      Ventricular end-diastolic pressures &ndash; Right and left ventricular end-diastolic pressures (RVEDP and LVEDP) are equal or nearly equal in constrictive pericarditis, while LVEDP is usually higher than RVEDP in restrictive cardiomyopathy. However, in many cases of restrictive cardiomyopathy the plateau of diastolic pressure is equally elevated in both ventricles as typically occurs in constrictive pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link&amp;anchor=H15#H15\">",
"       \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\", section on 'Cardiac catheterization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the rare patient in whom the hemodynamic and imaging studies fail to establish the diagnosis, endomyocardial or pericardial biopsy may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188582004\">",
"    <span class=\"h2\">",
"     Comparison with cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several similarities exist in the clinical presentation of constrictive pericarditis and cardiac tamponade. However, these entities differ in their effects on diastolic ventricular filling, which can lead to different findings on physical examination, echocardiography, and invasive hemodynamic assessment. A detailed discussion of these similarities and differences is presented in the UpToDate topic on cardiac tamponade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H2546629#H2546629\">",
"     \"Cardiac tamponade\", section on 'Comparison with constrictive pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12858506\">",
"    <span class=\"h2\">",
"     Comparison with chronic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with constrictive pericarditis presenting with ascites as the main manifestation are often thought to have cirrhosis, sometimes considered cryptogenic because the history does not reveal an obvious cause. Common physical examination findings in both constrictive pericarditis and chronic liver disease include peripheral edema, ascites, pulsatile hepatomegaly (part of the syndrome of congestive hepatopathy), and pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/11\">",
"     11",
"    </a>",
"    ]. These findings may lead to the misdiagnosis of chronic liver disease.",
"   </p>",
"   <p>",
"    The evaluation of jugular venous pressure (JVP) can help distinguish constrictive pericarditis from chronic liver disease. In constrictive pericarditis, there is marked elevation in JVP with characteristic changes in the morphology of the jugular venous pulsations (",
"    <a class=\"graphic graphic_figure graphicRef80995 \" href=\"UTD.htm?40/1/40976\">",
"     figure 1",
"    </a>",
"    ). In patients with cirrhosis from chronic liver disease, unless there is tense ascites, JVP is normal or only slightly elevated. JVP in patients with tense ascites should rapidly normalize following removal of some of the ascitic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of edema in adults\", section on 'Distribution of edema and central venous pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=see_link\">",
"     \"Congestive hepatopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The constrictive symptoms of constrictive pericarditis are permanent and often progressive in the majority of patients unless the constrictive pericarditis is surgically treated with pericardiectomy. Constriction is transient or reversible in a minority of patients with constrictive pericarditis. Thus, in the absence of evidence that the condition is chronic (eg, cachexia, atrial fibrillation, hepatic dysfunction, or pericardial calcification), patients with newly diagnosed constrictive pericarditis who are hemodynamically stable may be given a trial of conservative management for two to three months before pericardiectomy is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Transient constrictive pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with constrictive pericarditis undergo spontaneous resolution of constrictive pericarditis or respond to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In a review of 212 patients with echocardiographic findings of constrictive pericarditis, 17 percent had follow-up studies showing resolution at an interval ranging from two months to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/42\">",
"     42",
"    </a>",
"    ]. The most common cause of transient constrictive pericarditis was pericardial inflammation after pericardiotomy (25 percent of cases); infection (viral, bacterial, or tuberculous), idiopathic, collagen vascular disease, trauma, and malignancy accounted for the remaining cases. Treatment had included nonsteroidal antiinflammatory drugs, steroids, antibiotics, chemotherapy, and angiotensin converting enzyme inhibitors plus diuretics. Five patients had resolution of constriction without any specific therapy.",
"   </p>",
"   <p>",
"    Cardiac magnetic resonance (CMR) imaging, specifically the degree of late gadolinium enhancement (LGE) of the pericardium, appears promising as a way to predict which patients with constrictive pericarditis will have reversal or resolution of the process. In a retrospective cohort study of 29 patients with constrictive pericarditis who underwent CMR prior to receiving antiinflammatory medications, 14 of the 29 patients ultimately had resolution of constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/34\">",
"     34",
"    </a>",
"    ]. There was significantly greater baseline LGE pericardial thickness (4 mm versus 2 mm) and greater LGE qualitative intensity in those with persistent constrictive pericarditis than in the group of patients who ultimately had resolution of constrictive pericarditis. LGE pericardial thickness &ge;3 mm predicted reversibility of constriction with 86 percent sensitivity and 80 percent specificity.",
"   </p>",
"   <p>",
"    The clinical course in these patients implies the presence of acute inflammatory pericarditis with constriction due to inflammation that resolved after standard treatment with antiinflammatory agents for acute pericarditis. For patients with newly diagnosed constrictive pericarditis who are hemodynamically stable and without evidence of chronic constriction, we suggest a trial of conservative management rather than pericardiectomy. Conservative management with anti-inflammatory agents can be continued for two to three months before proceeding with pericardiectomy, if indicated. Patients with markers of chronic constriction (eg, cachexia, atrial fibrillation, hepatic dysfunction, or pericardial calcification) or signs of progressive systemic congestion (eg, dyspnea, unexplained weight gain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a new or increased pleural effusion or ascites) should undergo earlier surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link&amp;anchor=H2638284#H2638284\">",
"     \"Etiology of pericardial disease\", section on 'Acute pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chronic constrictive pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardiectomy is the only definitive treatment option for patients with chronic constrictive pericarditis. Medical therapy (ie, diuretics) may be used as a temporizing measure and for patients who are not candidates for surgery. While the majority of patients have a significant improvement in symptoms following pericardiectomy, there is a significant perioperative morbidity and mortality. Outcomes are best at high volume surgical centers with greater experience performing pericardiectomy.",
"   </p>",
"   <p>",
"    Removal of the thickened and inflamed pericardium is technically challenging. Efforts should be made to remove as much of the pericardium as is technically feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/5,12,43\">",
"     5,12,43",
"    </a>",
"    ]. Most patients have relief of symptoms after pericardiectomy. In one series, NYHA functional class improved markedly among long-term survivors (mean follow-up four years), with 69 percent free of clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/4\">",
"     4",
"    </a>",
"    ]. Surgical removal of the pericardium has a significant operative mortality. In one series of patients who underwent surgery between 1970 and 1985, the operative mortality was 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/3\">",
"     3",
"    </a>",
"    ]. A lower mortality rate of between 4 and 8 percent has been noted in patients who underwent pericardiectomy between 1977 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/4,5,43-45\">",
"     4,5,43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pericardiectomy is the accepted standard of treatment in patients with chronic constrictive pericarditis who have persistent and prominent symptoms. Preoperative diuretics should be used sparingly with the goal of reducing elevated venous pressure, ascites, and edema. This approach can help to optimize the patient&rsquo;s hemodynamics prior to surgery and may improve their functional status. Diuretics can also be considered for the palliative control of symptoms in patients who are not candidates for surgery.",
"   </p>",
"   <p>",
"    Due to the complex nature of the surgery and the associated operative mortality, surgery should be considered cautiously in patients with either mild or very advanced disease and in those with radiation-induced constriction, myocardial dysfunction, significant renal dysfunction, or mixed constrictive-restrictive disease. Such patients may not benefit from pericardiectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with constrictive pericarditis, mild symptoms, and a mild to moderate increase in central venous pressure with little or no edema, the surgical risk of pericardiectomy likely outweighs any potential benefit. A trial of medical management can be considered in such patients, with reassessment for pericardiectomy should symptoms progress [",
"      <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In our experience, patients with \"end-stage\" constrictive pericarditis derive little or no benefit from pericardiectomy and the operative risk is markedly elevated. Manifestations of end-stage disease include cachexia, reduced cardiac output (cardiac index &le;1.2",
"      <span class=\"nowrap\">",
"       L/m2",
"      </span>",
"      per min) at rest, and hypoalbuminemia due to protein losing enteropathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impaired hepatic function due to chronic congestion or cardiogenic cirrhosis.",
"     </li>",
"     <li>",
"      Symptoms may persist after successful pericardiectomy in patients with mixed constrictive-restrictive disease (eg, radiation-induced disease) because of abnormalities in intrinsic myocardial compliance. In these patients it is important to assess the extent of myocardial damage with tissue Doppler",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      endomyocardial biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term survival after pericardiectomy is inferior to that of an age- and sex-matched population. In one series, the five and ten year survival rates were 78 and 57 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/4\">",
"     4",
"    </a>",
"    ]. Independent adverse predictors of long-term outcome included older age and worse NYHA class. In another series, independent adverse predictors included older age, renal dysfunction, pulmonary hypertension, left ventricular dysfunction, and hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of the pericardial disease is also an important determinant of survival [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Prior ionizing radiation, because it may induce myocardial injury as well as pericardial disease, is associated with poorer long-term outcomes following surgery. In one series, the seven-year survival rates after surgery for patients with idiopathic, postsurgical, and radiation-induced constrictive pericarditis were 88, 66, and 27 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperative indices of contraction and relaxation also predict postoperative prognosis. An observational study of 40 patients undergoing preoperative cardiac catheterization reported that patients with both an abnormal rate of left ventricular pressure decline (+ LV",
"    <span class=\"nowrap\">",
"     dP/dt",
"    </span>",
"    &lt;1200",
"    <span class=\"nowrap\">",
"     mmHg/s)",
"    </span>",
"    and an abnormal time constant of LV isovolumic relaxation (tau &gt;50 ms) required more frequent postoperative inotropic support, had higher immediate postoperative mortality, and significantly lower long-term survival (median follow-up 2.4 years) than patients with either two normal values or one abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OCCULT CONSTRICTIVE PERICARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report in 1977 described 19 patients with a syndrome called occult constrictive pericardial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/9\">",
"     9",
"    </a>",
"    ]. The symptom complex of this proposed syndrome was comprised of chest pain, dyspnea, and fatigue. Risk factors and examination findings consistent with constrictive pericarditis in this patient population included a history of acute pericarditis in 12 patients (which was recurrent in five), pericardial calcification in 2 patients, and nonspecific repolarization changes in 16 patients. A plausible cause for pericardial disease was present in 10. The authors proposed that very mild constrictive pericarditis can cause these symptoms in the absence of abnormal physical or hemodynamic findings when the patient is evaluated in the basal state.",
"   </p>",
"   <p>",
"    To test this hypothesis, they measured hemodynamics invasively before and after infusing a liter or warm saline over a period of six to eight minutes to determine if occult constriction would then become overt. Six patients known not to have heart disease and 12 patients with myocardial disease served as controls.",
"   </p>",
"   <p>",
"    The results can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saline infusion caused an elevation and equalization of ventricular filling pressures, and development of pressure waveforms in diastole characteristic of constrictive pericarditis (",
"      <a class=\"graphic graphic_waveform graphicRef70708 \" href=\"UTD.htm?38/20/39233\">",
"       waveform 3",
"      </a>",
"      ) in the patients presumed to have occult constriction.",
"     </li>",
"     <li>",
"      Ventricular filling pressures and diastolic waveform were unaltered in the subjects free from heart disease.",
"     </li>",
"     <li>",
"      The patients with myocardial disease developed elevated ventricular filling pressures, but unequally on the two sides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eleven of the symptomatic patients underwent pericardiectomy with dramatic improvement. All 11 cases had mild gross or histologic evidence of pericardial disease. The fluid challenge was repeated postoperatively in five of the patients, with normal hemodynamic findings.",
"   </p>",
"   <p>",
"    Despite these promising findings, little has subsequently been published on occult constrictive pericardial disease, and no additional case series or randomized studies have replicated these results. Even though the above study was conducted using high fidelity pressure tracings in a laboratory well known for high-quality hemodynamic studies, it is unclear why or how such mild constriction could cause disabling symptoms, or why chest pain was a feature. Furthermore, the dramatic relief by pericardiectomy is unexplained in these patients with normal venous pressures that were modestly elevated by a rapid fluid challenge, and in whom the cardiac output was normal at rest and was not changed by the infusion.",
"   </p>",
"   <p>",
"    A saline infusion test looking for occult constrictive pericarditis is seldom indicated and, if performed, the results should not be the sole evidence leading to pericardiectomy. Patients suspected of having occult pericardial constrictive disease should undergo cardiac catheterization, including measurement of oxygen consumption during progressive bicycle exercise. A study of this nature would document exertional dyspnea and fatigue, and may help clarify the responsible mechanism. Rather than infusing fluid, diuretic therapy can be suspended for several days prior to cardiac catheterization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EFFUSIVE CONSTRICTIVE PERICARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pericardial cavity is typically obliterated in patients with constrictive pericarditis. Thus, even the normal amount of pericardial fluid is absent. However, pericardial effusion may be present in some cases. In this setting, the scarred pericardium not only constricts the cardiac volume but can also put pericardial fluid under increased pressure, leading to signs suggestive of cardiac tamponade. Pericardial pathology consistent with constrictive pericarditis with a concomitant effusion is called effusive constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/1,3,47-49\">",
"     1,3,47-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Incidence and etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effusive constrictive pericarditis appears to be relatively uncommon, although there are only limited published data. In one series of 95 patients undergoing surgery for constrictive pericarditis, 24 percent were diagnosed with effusive constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/3\">",
"     3",
"    </a>",
"    ]. In another series of 190 patients with cardiac tamponade who underwent pericardiocentesis and cardiac catheterization, effusive constrictive pericarditis was diagnosed in 15 patients (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of effusive constrictive pericarditis are idiopathic, reflecting the frequency of idiopathic pericardial disease in general [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/3,48\">",
"     3,48",
"    </a>",
"    ]. Other reported causes include radiation, malignancy, chemotherapy, infection, and postsurgical pericardial disease. Tuberculosis is a frequent cause of effusive constrictive pericarditis in regions where tuberculosis is common [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"     \"Tuberculous pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with effusive constrictive pericarditis usually present with clinical features of pericardial effusion or constrictive pericarditis or both. The following clinical observations were made in one series of 15 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms were usually present for less than three months (range 4 days to 26 months)",
"     </li>",
"     <li>",
"      All patients had jugular venous distention and hepatomegaly",
"     </li>",
"     <li>",
"      Eight patients had pericardial chest pain, fever, and a pericardial rub",
"     </li>",
"     <li>",
"      Pulsus paradoxus was seen in ten patients",
"     </li>",
"     <li>",
"      All patients were in normal sinus rhythm",
"     </li>",
"     <li>",
"      No patients had pericardial calcification",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of clinical clues suggest that a patient with suspected constrictive pericarditis may actually have effusive constrictive pericarditis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulsus paradoxus is often present; this finding is uncommon in classical constrictive pericarditis because the inspiratory decline in intrathoracic pressure is not transmitted to the right heart chambers. (See",
"      <a class=\"local\" href=\"#H15194964\">",
"       'Doppler'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pericardial knock is absent.",
"     </li>",
"     <li>",
"      The Y descent is less marked than expected. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hemodynamic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kussmaul's sign is frequently absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of effusive constrictive pericarditis often becomes apparent during pericardiocentesis in patients initially considered to have uncomplicated cardiac tamponade. In such cases, the right atrial pressure remains abnormal after removal of the pericardial effusion due to constriction by the visceral pericardium. Right heart pressures and systemic arterial blood pressure should be monitored simultaneously during elective pericardiocentesis in order to allow for the detection of effusive constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to pericardiocentesis, effusive constrictive pericarditis is suggested by the unexpected persistence of the v wave of right atrial pressure. The diagnosis is further supported by the following findings on the right atrial pressure tracing after pericardiocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistence of elevated right atrial pressure despite lowering of the pericardial pressure to near zero with pericardiocentesis",
"     </li>",
"     <li>",
"      The development of a marked, rapid y descent",
"     </li>",
"     <li>",
"      The lack of an inspiratory decline in right atrial pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By definition, in patients with effusive constrictive pericarditis, pericardiocentesis fails to decrease the right atrial pressure by 50 percent or to a level below 10 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/48\">",
"     48",
"    </a>",
"    ]. A persistently elevated right atrial pressure after pericardiocentesis may also be due to right heart failure or tricuspid regurgitation. Thus, appropriate studies should be performed to exclude these disorders before making the diagnosis of effusive constrictive pericarditis.",
"   </p>",
"   <p>",
"    Noninvasive imaging is not useful to confirm the diagnosis of effusive constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/49\">",
"     49",
"    </a>",
"    ]. The visceral layer of pericardium, which is responsible for the constrictive component of this process, is not typically thickened to a degree that is detectable on imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardiocentesis alone may produce at least temporary relief of symptoms in patients with effusive constrictive pericarditis, although it does not fully reverse the underlying condition. In a series of 15 patients, marked improvement after pericardiocentesis was noted in five, mild improvement in eight, and no benefit in two [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In effusive constrictive pericarditis, it is mainly the visceral layer of pericardium, not the parietal layer, which constricts the heart. Thus, if surgery is required, a visceral pericardiectomy must be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/49\">",
"     49",
"    </a>",
"    ]. However, the visceral component of the pericardiectomy is often difficult, requiring sharp dissection of many small fragments until an improvement in ventricular motion is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/12/12490/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, pericardiectomy for effusive constrictive pericarditis should be performed only at centers with experience in pericardiectomy for constrictive pericarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21327782\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The critical pathophysiologic features of constrictive pericarditis, which are responsible for the physical exam, hemodynamic, and imaging findings, are (see",
"      <a class=\"local\" href=\"#H188581749\">",
"       'Physiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Greatly enhanced ventricular interaction or interdependence",
"     </li>",
"     <li>",
"      The dissociation of intracardiac and intrathoracic pressures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constrictive pericarditis can occur after virtually any pericardial disease process, but most often follows acute pericarditis (viral or idiopathic) or cardiac surgery. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of patients with constrictive pericarditis display elevated jugular venous pressure (JVP) on physical examination. Other important but less common features include pulsus paradoxus, Kussmaul&rsquo;s sign, a pericardial knock, edema, ascites,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cachexia. (See",
"      <a class=\"local\" href=\"#H15913768\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected constrictive pericarditis should undergo initial evaluation with electrocardiography, chest radiography, and echocardiography. (See",
"      <a class=\"local\" href=\"#H274012956\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional testing is often required if the diagnosis of constrictive pericarditis remains uncertain or if surgical intervention is planned. We suggest using CMR imaging in patients being considered for pericardiectomy to provide additional detailed anatomic information that might alter the decision to proceed with surgery based on the likelihood of resolution with medical therapy alone. Computed tomography (CT) can provide additional detailed anatomic information about the extent of pericardial thickening and scarring. Invasive hemodynamic evaluation during cardiac catheterization can confirm the diagnosis and concurrent coronary angiography defines the patient&rsquo;s coronary anatomy prior to possible surgical intervention. (See",
"      <a class=\"local\" href=\"#H274012956\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common findings on imaging studies include pericardial thickening with or without calcification, dilatation of the inferior vena cava and hepatic veins (plethora) with absent or diminished inspiratory collapse, abnormal passive filling of the ventricles during early diastole, and pronounced respiratory variation in ventricular filling. (See",
"      <a class=\"local\" href=\"#H274012956\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms and physical findings in patients with constrictive pericarditis are similar to those of several other disorders. Most importantly, the clinician must distinguish between constrictive pericarditis, which is treated by pericardiectomy; cardiac tamponade, which is treated by drainage of the pericardial effusion; and disorders such as restrictive cardiomyopathy and cirrhosis, which require markedly different treatment. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with newly diagnosed constrictive pericarditis who are hemodynamically stable and without evidence of chronic constriction (ie, no evidence of cachexia, weight loss, reduced cardiac output at rest, or hypoalbuminemia due to protein losing enteropathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impaired hepatic function due to chronic congestion or cardiogenic cirrhosis), we suggest a trial of conservative management rather than pericardiectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Transient constrictive pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardiectomy is the only definitive treatment option for patients with chronic symptomatic constrictive pericarditis. Medical therapy (ie, diuretics) may be used as a temporizing measure and for patients who are not candidates for surgery. While the majority of patients have a significant improvement in symptoms following pericardiectomy, there is a significant perioperative morbidity and mortality. Outcomes are best at high-volume surgical centers with greater experience performing pericardiectomy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Chronic constrictive pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardial pathology consistent with constrictive pericarditis with a concomitant effusion is called effusive constrictive pericarditis. The distinction from isolated cardiac tamponade becomes apparent by the unexpected persistence of an elevated right atrial pressure following pericardiocentesis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Effusive constrictive pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/1\">",
"      Hancock EW. Subacute effusive-constrictive pericarditis. Circulation 1971; 43:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/2\">",
"      Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/3\">",
"      Cameron J, Oesterle SN, Baldwin JC, Hancock EW. The etiologic spectrum of constrictive pericarditis. Am Heart J 1987; 113:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/4\">",
"      Ling LH, Oh JK, Schaff HV, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation 1999; 100:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/5\">",
"      Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 2004; 43:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/6\">",
"      Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation 2011; 124:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/7\">",
"      Bansal R, Perez L, Razzouk A, et al. Pericardial constriction after cardiac transplantation. J Heart Lung Transplant 2010; 29:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/8\">",
"      ROBERTSON R, ARNOLD CR. Constrictive pericarditis with particular reference to etiology. Circulation 1962; 26:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/9\">",
"      Bush CA, Stang JM, Wooley CF, Kilman JW. Occult constrictive pericardial disease. Diagnosis by rapid volume expansion and correction by pericardiectomy. Circulation 1977; 56:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/10\">",
"      Spodick DH. The normal and diseased pericardium: current concepts of pericardial physiology, diagnosis and treatment. J Am Coll Cardiol 1983; 1:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/11\">",
"      Maisch B, Seferovi PM, Risti AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/12\">",
"      Talreja DR, Edwards WD, Danielson GK, et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation 2003; 108:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/13\">",
"      Ling LH, Oh JK, Breen JF, et al. Calcific constrictive pericarditis: is it still with us? Ann Intern Med 2000; 132:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/14\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/15\">",
"      Schnittger I, Bowden RE, Abrams J, Popp RL. Echocardiography: pericardial thickening and constrictive pericarditis. Am J Cardiol 1978; 42:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/16\">",
"      Agatston AS, Rao A, Price RJ, Kinney EL. Diagnosis of constrictive pericarditis by pulsed Doppler echocardiography. Am J Cardiol 1984; 54:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/17\">",
"      Ling LH, Oh JK, Tei C, et al. Pericardial thickness measured with transesophageal echocardiography: feasibility and potential clinical usefulness. J Am Coll Cardiol 1997; 29:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/18\">",
"      Engel PJ, Fowler NO, Tei CW, et al. M-mode echocardiography in constrictive pericarditis. J Am Coll Cardiol 1985; 6:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/19\">",
"      Boonyaratavej S, Oh JK, Tajik AJ, et al. Comparison of mitral inflow and superior vena cava Doppler velocities in chronic obstructive pulmonary disease and constrictive pericarditis. J Am Coll Cardiol 1998; 32:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/20\">",
"      Tei C, Child JS, Tanaka H, Shah PM. Atrial systolic notch on the interventricular septal echogram: an echocardiographic sign of constrictive pericarditis. J Am Coll Cardiol 1983; 1:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/21\">",
"      Hoit BD. Imaging the pericardium. Cardiol Clin 1990; 8:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/22\">",
"      D'Cruz IA, Dick A, Gross CM, et al. Abnormal left ventricular-left atrial posterior wall contour: a new two-dimensional echocardiographic sign in constrictive pericarditis. Am Heart J 1989; 118:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/23\">",
"      Ha JW, Oh JK, Ling LH, et al. Annulus paradoxus: transmitral flow velocity to mitral annular velocity ratio is inversely proportional to pulmonary capillary wedge pressure in patients with constrictive pericarditis. Circulation 2001; 104:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/24\">",
"      Veress G, Ling LH, Kim KH, et al. Mitral and tricuspid annular velocities before and after pericardiectomy in patients with constrictive pericarditis. Circ Cardiovasc Imaging 2011; 4:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/25\">",
"      Sun JP, Abdalla IA, Yang XS, et al. Respiratory variation of mitral and pulmonary venous Doppler flow velocities in constrictive pericarditis before and after pericardiectomy. J Am Soc Echocardiogr 2001; 14:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/26\">",
"      Oh JK, Hatle LK, Seward JB, et al. Diagnostic role of Doppler echocardiography in constrictive pericarditis. J Am Coll Cardiol 1994; 23:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/27\">",
"      Oh JK, Tajik AJ, Appleton CP, et al. Preload reduction to unmask the characteristic Doppler features of constrictive pericarditis. A new observation. Circulation 1997; 95:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/28\">",
"      Rienm&uuml;ller R, Doppman JL, Lissner J, et al. Constrictive pericardial disease: prognostic significance of a nonvisualized left ventricular wall. Radiology 1985; 156:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/29\">",
"      Verhaert D, Gabriel RS, Johnston D, et al. The role of multimodality imaging in the management of pericardial disease. Circ Cardiovasc Imaging 2010; 3:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/30\">",
"      Sechtem U, Tscholakoff D, Higgins CB. MRI of the normal pericardium. AJR Am J Roentgenol 1986; 147:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/31\">",
"      Breen JF. Imaging of the pericardium. J Thorac Imaging 2001; 16:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/32\">",
"      Kojima S, Yamada N, Goto Y. Diagnosis of constrictive pericarditis by tagged cine magnetic resonance imaging. N Engl J Med 1999; 341:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/33\">",
"      Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. Radiology 1992; 182:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/34\">",
"      Feng D, Glockner J, Kim K, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. Circulation 2011; 124:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/35\">",
"      Zurick AO, Bolen MA, Kwon DH, et al. Pericardial delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis undergoing surgical pericardiectomy: a case series with histopathological correlation. JACC Cardiovasc Imaging 2011; 4:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/36\">",
"      Hurrell DG, Nishimura RA, Higano ST, et al. Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Circulation 1996; 93:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/37\">",
"      Rajagopalan N, Garcia MJ, Rodriguez L, et al. Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy. Am J Cardiol 2001; 87:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/38\">",
"      Schoenfeld MH, Supple EW, Dec GW Jr, et al. Restrictive cardiomyopathy versus constrictive pericarditis: role of endomyocardial biopsy in avoiding unnecessary thoracotomy. Circulation 1987; 75:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/39\">",
"      Maisch B, Bethge C, Drude L, et al. Pericardioscopy and epicardial biopsy--new diagnostic tools in pericardial and perimyocardial disease. Eur Heart J 1994; 15 Suppl C:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/40\">",
"      Guazzi M, Polese A, Magrini F, et al. Negative influences of ascites on the cardiac function of cirrhotic patients. Am J Med 1975; 59:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/41\">",
"      Sagrist&agrave;-Sauleda J, Permanyer-Miralda G, Candell-Riera J, et al. Transient cardiac constriction: an unrecognized pattern of evolution in effusive acute idiopathic pericarditis. Am J Cardiol 1987; 59:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/42\">",
"      Haley JH, Tajik AJ, Danielson GK, et al. Transient constrictive pericarditis: causes and natural history. J Am Coll Cardiol 2004; 43:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/43\">",
"      Chowdhury UK, Subramaniam GK, Kumar AS, et al. Pericardiectomy for constrictive pericarditis: a clinical, echocardiographic, and hemodynamic evaluation of two surgical techniques. Ann Thorac Surg 2006; 81:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/44\">",
"      DeValeria PA, Baumgartner WA, Casale AS, et al. Current indications, risks, and outcome after pericardiectomy. Ann Thorac Surg 1991; 52:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/45\">",
"      Ghavidel AA, Gholampour M, Kyavar M, et al. Constrictive pericarditis treated by surgery. Tex Heart Inst J 2012; 39:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/46\">",
"      Ha JW, Oh JK, Schaff HV, et al. Impact of left ventricular function on immediate and long-term outcomes after pericardiectomy in constrictive pericarditis. J Thorac Cardiovasc Surg 2008; 136:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/47\">",
"      Hancock EW. On the elastic and rigid forms of constrictive pericarditis. Am Heart J 1980; 100:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/48\">",
"      Sagrist&agrave;-Sauleda J, Angel J, S&aacute;nchez A, et al. Effusive-constrictive pericarditis. N Engl J Med 2004; 350:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/49\">",
"      Hancock EW. A clearer view of effusive-constrictive pericarditis. N Engl J Med 2004; 350:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/12/12490/abstract/50\">",
"      Hugo-Hamman CT, Scher H, De Moor MM. Tuberculous pericarditis in children: a review of 44 cases. Pediatr Infect Dis J 1994; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     Shabetai R. The Pericardium, Kluwer Academic Publishers, Norwell, MA 2003. p.227.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4938 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12490=[""].join("\n");
var outline_f12_12_12490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21327782\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188581749\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15913768\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274012956\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15194949\">",
"      - Two-dimensional and M mode",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15194964\">",
"      - Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hemodynamic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12858639\">",
"      Plasma BNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12858374\">",
"      Comparison with restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H188582004\">",
"      Comparison with cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12858506\">",
"      Comparison with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Transient constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chronic constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OCCULT CONSTRICTIVE PERICARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EFFUSIVE CONSTRICTIVE PERICARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Incidence and etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment and course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21327782\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4938\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4938|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/18/12578\" title=\"diagnostic image 1\">",
"      Lateral CXR showing pericardial calcium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4938|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/1/40976\" title=\"figure 1\">",
"      Jugular venous pulse in constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/59/7097\" title=\"figure 2\">",
"      Dip and plateau in constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4938|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/27/32180\" title=\"waveform 1\">",
"      Pulsus alternans and pulsus paradoxus arterial waveforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?18/54/19296\" title=\"waveform 2\">",
"      Equalization of pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/20/39233\" title=\"waveform 3\">",
"      Saline in occult constriction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=related_link\">",
"      Congestive hepatopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27077?source=related_link\">",
"      Echocardiographic evaluation of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=related_link\">",
"      Pulsus paradoxus in pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=related_link\">",
"      Tuberculous pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_12_12491="Causes of ascites";
var content_f12_12_12491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of ascites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cirrhosis",
"        </strong>",
"       </td>",
"       <td>",
"        81 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cancer",
"        </strong>",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Heart failure",
"        </strong>",
"       </td>",
"       <td>",
"        3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tuberculosis",
"        </strong>",
"       </td>",
"       <td>",
"        2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dialysis",
"        </strong>",
"       </td>",
"       <td>",
"        1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pancreatic disease",
"        </strong>",
"       </td>",
"       <td>",
"        1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Other",
"        </strong>",
"       </td>",
"       <td>",
"        2 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Runyon BA, Montano AA, Akriviadis EA, et al. Ann Intern Med 1992; 117:215.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12491=[""].join("\n");
var outline_f12_12_12491=null;
var title_f12_12_12492="Mass rx for lymphatic filariasis_onchocerciasis and or loiasis";
var content_f12_12_12492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to mass treatment of lymphatic filariasis, onchocerciasis, and/or loiasis in settings of monoinfection or coinfection*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Lymphatic filariasis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onchocerciasis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loiasis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment regimen of choice",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindicated agent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td>",
"        Diethylcarbamazine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td>",
"        Ivermectin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td>",
"        (Mass treatment not in place)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td>",
"        Doxycycline plus ivermectin or albendazole",
"       </td>",
"       <td>",
"        Diethylcarbamazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         (Caution advised re mass treatment in such settings)",
"        </span>",
"       </td>",
"       <td>",
"        Diethylcarbamazine (contraindicated for L. loa microfilariae load &gt;2500/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td>",
"        Doxycycline plus albendazole",
"       </td>",
"       <td>",
"        Ivermectin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    * Dosing and duration are outlined in the text; see related topics.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Weller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12492=[""].join("\n");
var outline_f12_12_12492=null;
var title_f12_12_12493="Clinical features of HHT";
var content_f12_12_12493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of hereditary hemorrhagic telangiecasia (HHT)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Presentation patterns",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis and signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Nasal telangiectasia",
"       </td>",
"       <td rowspan=\"4\">",
"        &gt;90 percent",
"       </td>",
"       <td rowspan=\"4\">",
"        Nose bleeds are usually the first manifestation of HHT, frequently commencing in childhood.",
"       </td>",
"       <td rowspan=\"4\">",
"        History, inspection",
"       </td>",
"       <td>",
"        1)",
"        <strong>",
"         Routine therapy:",
"        </strong>",
"        Packing, humidification, iron, and transfusions when needed. Estrogen/progesterone therapy proposed (in view of possible induction of squamous metaplasia) but no benefit in only controlled trial.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2)",
"        <strong>",
"         Laser treatment",
"        </strong>",
"        successful. Argon and KTP lasers which use wavelengths maximally absorbed by hemoglobin often preferred to Nd-YAG which carries a higher risk of cartilage absorption and septal perforation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3)",
"        <strong>",
"         Surgery,",
"        </strong>",
"        such as septal dermoplasty to replace thin nasal mucosa with a tougher skin graft, is successful in expert hands, though vessels regrow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4)",
"        <strong>",
"         Other:",
"        </strong>",
"        Therapeutic embolization may be difficult because of extensive anastamoses; cauterization has only a limited role.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucocutaneous telangiectasia",
"       </td>",
"       <td>",
"        50 to 80 percent",
"       </td>",
"       <td>",
"        Increase in size and number with age. Main concerns are cosmetic. May hemorrhage.",
"       </td>",
"       <td>",
"        Inspection (oral, mucosa, conjunctivae, face, trunk, extremities, nail beds)",
"       </td>",
"       <td>",
"        Generally not indicated, but laser therapy can be used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal telangiectasia",
"       </td>",
"       <td>",
"        11 to 40 percent",
"       </td>",
"       <td>",
"        Onset generally over 30 years: iron deficiency anemia, occasionally acute gastrointestinal hemorrhage.",
"       </td>",
"       <td>",
"        Flexible endoscopy, endoscopy angiogram, capsule endoscopy",
"       </td>",
"       <td>",
"        Iron supplementation and transfusion are the mainstays of treatment. Estrogen-progesterone, and laser therapy beneficial. The role of antifibrinolytics is unclear.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary AVMs",
"       </td>",
"       <td>",
"        11 to 30 percent",
"       </td>",
"       <td>",
"        Cyanosis, clubbing, bruit, dyspnea, paradoxical embolism, cerebral abscess.",
"       </td>",
"       <td>",
"        Chest radiography, blood gas measurement, helical CT, angiography, chest echocardiography",
"       </td>",
"       <td>",
"        Therapeutic embolization, surgical resection, ligation of arterial supply (artery ligation is only of historical interest).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral AVMs",
"       </td>",
"       <td>",
"        10 to 15 percent",
"       </td>",
"       <td>",
"        Headache, epilepsy, ischemia, intracerebral hemorrhage.",
"       </td>",
"       <td>",
"        CT, MRI, Doppler Sonography, angiography",
"       </td>",
"       <td>",
"        Therapeutic embolization, neurovascular surgery, stereotactic radiosurgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic AVMs",
"       </td>",
"       <td>",
"        Up to 74 percent*",
"       </td>",
"       <td>",
"        Usually silent. Hepatic artery-hepatic vein AVMS: hyperdynamic circulation. Portasystemic shunts: ascites and encephalopathy.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Therapeutic embolization, liver transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conjunctival telangiectasia",
"       </td>",
"       <td>",
"        35 percent",
"       </td>",
"       <td>",
"        Usually silent. May have \"bloody tears\".",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AVM: arteriovenous malformation; KTP: potassium titanyl phosphate; MRI: magnetic resonance imaging; YAG: yttrium-aluminum-garnet.",
"     <br>",
"      * Data from: Ianora AA, Memeo M, Sabba C, et al. Hereditary hemorrhagic telangiectasia: mlt-detector row helical CT assessment of hepatic involvement. Radiology 2004; 230:250.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Shovlin CL, Letarte M. Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12493=[""].join("\n");
var outline_f12_12_12493=null;
var title_f12_12_12494="Recommended scrn over 65 yrs";
var content_f12_12_12494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of screening and counseling recommendations for adults age &ge;65 years",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Priority problem",
"       </td>",
"       <td class=\"subtitle1\">",
"        Brief recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Historical information and counseling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exercise",
"       </td>",
"       <td>",
"        <p>",
"         Moderate to vigorous aerobic activity 3-5 times per week",
"        </p>",
"        <p>",
"         Weight training or resistance exercises to maintain strength",
"        </p>",
"        <p>",
"         Flexibility activities to maintain range of motion",
"        </p>",
"        <p>",
"         Balance training to improve stability and prevent falls",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol use",
"       </td>",
"       <td>",
"        <p>",
"         CAGE questionnaire",
"        </p>",
"        <p>",
"         Counseling to stop drinking",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tobacco use",
"       </td>",
"       <td>",
"        <p>",
"         Ongoing regular counseling to stop smoking",
"        </p>",
"        <p>",
"         Consideration of pharmacotherapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Medication use",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Regular review of medication list for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Completeness, accuracy, adherence, and affordability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drug-drug, drug-disease interactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Careful attention to use of specific drug types/classes including warfarin, digoxin, antidiabetic, analgesic, antihypertensive, psychotropic, and anticholinergic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinary incontinence (UI)",
"       </td>",
"       <td>",
"        <p>",
"         Inquire about presence and severity biannually",
"        </p>",
"        <p>",
"         Presence of UI should trigger medication review, GU exam, appropriate blood and urine tests",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Driving",
"       </td>",
"       <td>",
"        <p>",
"         Consideration of driving problems in those with problems with vision, mobility or cognition",
"        </p>",
"        <p>",
"         For demented patients, recommend stop driving or refer for detailed driving assessment",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Social support",
"       </td>",
"       <td>",
"        Regular screening for financial and social support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elder mistreatment",
"       </td>",
"       <td>",
"        Routine direct questioning about problems with abuse or neglect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Advance directives",
"       </td>",
"       <td>",
"        Discussion and documentation of preferences with living will and designation of health care power-of-attorney",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Physical examination and testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blood pressure",
"       </td>",
"       <td>",
"        <p>",
"         Measure every 1-2 years",
"        </p>",
"        <p>",
"         If treatment initiated, monitor orthostatic blood pressure, renal function and electrolytes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weight",
"       </td>",
"       <td>",
"        Weight loss of 10 percent or more per year triggers assessment of undernutrition, possible medical or medication-related causes, dental status, food security, food related functional status, appetite and intake, swallow ability and previous dietary restrictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hearing and vision",
"       </td>",
"       <td>",
"        <p>",
"         Annual screening for hearing loss with patient inquiry and exam (Whisper test or handheld audiometry)",
"        </p>",
"        <p>",
"         General ophthalmologic examination, including screening for glaucoma, every 1-2 years",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cognition",
"       </td>",
"       <td>",
"        Targeted screening in patients with memory complaints or new functional impairment with MMSE, Mini-Cog, Clock Drawing Test, or Memory Impairment Screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Mood",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Screen all older adults for depression with two questions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1) Feeling depressed or sad?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2) Loss of interest?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gait and balance",
"       </td>",
"       <td>",
"        Get Up and Go Test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipids",
"       </td>",
"       <td>",
"        Screen and treat older adults with CHD risk exceeding 10 percent over ten years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bone density",
"       </td>",
"       <td>",
"        Screening densitometry for osteoporosis for women beginning at age 65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal aortic aneurysm",
"       </td>",
"       <td>",
"        One time screening ultrasound in men aged 65-75 with any history of smoking or family history of AAA requiring repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cancer screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Cancer screening",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Key considerations in older adults:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Life expectancy: will this patient live long enough to benefit?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Potential harms: procedural complications, anxiety, cost and overdiagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Individual patient preference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer",
"       </td>",
"       <td>",
"        Screening mammography every 1-2 years as long as life expectancy at least 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colorectal cancer",
"       </td>",
"       <td>",
"        <p>",
"         Annual FOBT v.",
"        </p>",
"        <p>",
"         Screening colonoscopy every 10 years v.",
"        </p>",
"        <p>",
"         Flexible sigmoidoscopy every 5 years as long as life expectancy at least 5 years",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cervical cancer",
"       </td>",
"       <td>",
"        <p>",
"         May safely discontinue Pap smears at or after age 65 after 3 consecutive normals within 10 year period",
"        </p>",
"        <p>",
"         May discontinue after hysterectomy for benign indication",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Immunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tetanus-diptheria vaccine",
"       </td>",
"       <td>",
"        Booster every 10 years in patients who have received primary series (alternative: booster once after age 50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza vaccine",
"       </td>",
"       <td>",
"        Annual vaccination after age 65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumococcal vaccine",
"       </td>",
"       <td>",
"        <p>",
"         Vaccinate once after age 65",
"        </p>",
"        <p>",
"         Revaccinate once after age 65 if an initial vaccination was given before age 65 and five years have elapsed since the first dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes zoster vaccine",
"       </td>",
"       <td>",
"        One time vaccination after age 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirin",
"       </td>",
"       <td>",
"        <p>",
"         Consider daily aspirin in patients with 5 year CHD risk of 3 percent or greater",
"        </p>",
"        <p>",
"         Weigh risks of gastrointestinal bleeding",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium and Vitamin D",
"       </td>",
"       <td>",
"        1200 mg of elemental calcium (diet and/or supplement) and at least 800 IU of Vitamin D",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12494=[""].join("\n");
var outline_f12_12_12494=null;
var title_f12_12_12495="Synergistic tox of analgesics";
var content_f12_12_12495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Synergistic toxicity of analgesics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As shown to the left, when phenacetin or acetaminophen is ingested with aspirin, there is a potentiating nephrotoxic effect. The aspirin is converted to salicylate, which becomes highly concentrated and depletes glutathione in both the cortex and papillae of the kidney. With the cellular glutathione depleted, the reactive metabolite of acetaminophen then produces lipid peroxides and arylation of tissue proteins, ultimately resulting in necrosis of the papillae. Patients taking analgesic mixtures that contain aspirin, acetaminophen, and/or phenacetin plus potentially addicting compounds, such as codeine and caffeine, are more likely to abuse such drugs, thereby further enhancing the risk of analgesic nephropathy (as shown in the upper right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Duggin, G. Am J Kidney Dis 1996; 28:S39.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_12_12495=[""].join("\n");
var outline_f12_12_12495=null;
